0001078799 false 2021 FY 0001078799 2021-01-01 2021-12-31 0001078799 2021-12-31 0001078799 2022-04-15 0001078799 2020-12-31 0001078799 us-gaap:PreferredClassAMember 2021-12-31 0001078799 us-gaap:PreferredClassAMember 2020-12-31 0001078799 us-gaap:PreferredClassBMember 2021-12-31 0001078799 us-gaap:PreferredClassBMember 2020-12-31 0001078799 2020-01-01 2020-12-31 0001078799 MCOA:PreferredStockClassAMember 2019-12-31 0001078799 MCOA:PreferredStockClassBMember 2019-12-31 0001078799 us-gaap:CommonStockMember 2019-12-31 0001078799 MCOA:CommonStockToBeIssuedMember 2019-12-31 0001078799 MCOA:StockSubcriptionsMember 2019-12-31 0001078799 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001078799 us-gaap:RetainedEarningsMember 2019-12-31 0001078799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001078799 2019-12-31 0001078799 MCOA:PreferredStockClassAMember 2020-12-31 0001078799 MCOA:PreferredStockClassBMember 2020-12-31 0001078799 us-gaap:CommonStockMember 2020-12-31 0001078799 MCOA:CommonStockToBeIssuedMember 2020-12-31 0001078799 MCOA:StockSubcriptionsMember 2020-12-31 0001078799 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001078799 us-gaap:RetainedEarningsMember 2020-12-31 0001078799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001078799 MCOA:PreferredStockClassAMember 2020-01-01 2020-12-31 0001078799 MCOA:PreferredStockClassBMember 2020-01-01 2020-12-31 0001078799 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001078799 MCOA:CommonStockToBeIssuedMember 2020-01-01 2020-12-31 0001078799 MCOA:StockSubcriptionsMember 2020-01-01 2020-12-31 0001078799 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001078799 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001078799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001078799 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001078799 MCOA:PreferredStockClassAMember 2021-01-01 2021-12-31 0001078799 MCOA:PreferredStockClassBMember 2021-01-01 2021-12-31 0001078799 MCOA:CommonStockToBeIssuedMember 2021-01-01 2021-12-31 0001078799 MCOA:StockSubcriptionsMember 2021-01-01 2021-12-31 0001078799 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001078799 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001078799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001078799 MCOA:PreferredStockClassAMember 2021-12-31 0001078799 MCOA:PreferredStockClassBMember 2021-12-31 0001078799 us-gaap:CommonStockMember 2021-12-31 0001078799 MCOA:CommonStockToBeIssuedMember 2021-12-31 0001078799 MCOA:StockSubcriptionsMember 2021-12-31 0001078799 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001078799 us-gaap:RetainedEarningsMember 2021-12-31 0001078799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001078799 MCOA:SparrowtechIncMember 2009-10-01 2009-10-31 0001078799 us-gaap:PropertyPlantAndEquipmentMember srt:MinimumMember 2021-01-01 2021-12-31 0001078799 us-gaap:PropertyPlantAndEquipmentMember srt:MaximumMember 2021-01-01 2021-12-31 0001078799 MCOA:InvestorsMember 2021-01-01 2021-12-31 0001078799 MCOA:InvestorsMember 2021-12-31 0001078799 us-gaap:SubsequentEventMember 2022-02-17 0001078799 2020-08-07 0001078799 us-gaap:SubsequentEventMember MCOA:RestrictedCommonStockMember 2022-03-29 2022-04-02 0001078799 us-gaap:SubsequentEventMember 2022-04-05 0001078799 2021-05-25 0001078799 us-gaap:SubsequentEventMember MCOA:RestrictedCommonStockMember 2022-04-01 2022-04-06 0001078799 us-gaap:SubsequentEventMember 2022-04-01 2022-04-07 0001078799 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-12-31 0001078799 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-12-31 0001078799 MCOA:OptionsToPurchaseCommonStockMember 2021-01-01 2021-12-31 0001078799 MCOA:OptionsToPurchaseCommonStockMember 2020-01-01 2020-12-31 0001078799 MCOA:WarrantsToPurchaseCommonStockMember 2021-01-01 2021-12-31 0001078799 MCOA:WarrantsToPurchaseCommonStockMember 2020-01-01 2020-12-31 0001078799 MCOA:HempSmartMember 2021-01-01 2021-12-31 0001078799 MCOA:HempSmartMember 2020-01-01 2020-12-31 0001078799 MCOA:CdistroMember 2021-01-01 2021-12-31 0001078799 MCOA:CdistroMember 2020-01-01 2020-12-31 0001078799 us-gaap:ComputerEquipmentMember 2021-12-31 0001078799 us-gaap:ComputerEquipmentMember 2020-12-31 0001078799 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001078799 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001078799 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001078799 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001078799 MCOA:JointVentureAgreementWithBougainvilleVenturesIncMember 2017-03-16 0001078799 MCOA:JointVentureAgreementWithBougainvilleVenturesIncMember srt:MaximumMember 2017-11-06 0001078799 MCOA:JointVentureAgreementWithBougainvilleVenturesIncMember srt:MinimumMember 2017-11-06 0001078799 MCOA:JointVentureAgreementWithBougainvilleVenturesIncMember us-gaap:RestrictedStockMember 2017-11-01 2017-11-09 0001078799 MCOA:JointVentureAgreementWithBougainvilleVenturesIncMember us-gaap:RestrictedStockMember 2017-11-01 2017-11-07 0001078799 MCOA:JointVentureAgreementWithBougainvilleVenturesIncMember 2018-08-10 0001078799 2017-01-01 2017-12-31 0001078799 2017-12-31 0001078799 2018-01-01 2018-03-31 0001078799 2018-07-01 2018-09-30 0001078799 2018-01-01 2018-12-31 0001078799 srt:MaximumMember MCOA:NaturalPlantExtractMember 2019-04-15 0001078799 srt:MinimumMember MCOA:NaturalPlantExtractMember 2019-04-15 0001078799 MCOA:NaturalPlantExtractMember 2020-02-01 2020-02-03 0001078799 MCOA:NaturalPlantExtractMember 2020-02-03 0001078799 MCOA:CannabisGlobalIncMember 2020-09-30 0001078799 MCOA:CannabisGlobalIncMember srt:MinimumMember 2020-09-30 0001078799 MCOA:CannabisGlobalIncMember srt:MaximumMember 2020-09-30 0001078799 MCOA:EcoInnovationGroupIncMember 2021-02-26 0001078799 MCOA:ECOXMember srt:MinimumMember 2021-09-30 0001078799 MCOA:ECOXMember srt:MaximumMember 2021-09-30 0001078799 MCOA:HempsmartBrazilMember 2020-09-30 0001078799 MCOA:FirstConvertiblePromissoryNotesMember 2017-12-09 0001078799 MCOA:SecondConvertiblePromissoryNotesMember 2018-02-13 0001078799 MCOA:InvestmentMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2018-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2018-12-31 0001078799 MCOA:InvestmentMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-01-01 2019-03-31 0001078799 MCOA:InvestmentMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2019-03-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-03-31 0001078799 MCOA:InvestmentMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-04-01 2019-06-30 0001078799 MCOA:InvestmentMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2019-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-06-30 0001078799 MCOA:InvestmentMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-07-01 2019-09-30 0001078799 MCOA:InvestmentMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2019-09-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-09-30 0001078799 MCOA:InvestmentMember 2019-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2019-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2019-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2019-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2019-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2019-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2019-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2019-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2019-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-10-01 2020-12-31 0001078799 MCOA:InvestmentMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2019-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2019-12-31 0001078799 MCOA:InvestmentMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-01-01 2020-03-31 0001078799 MCOA:InvestmentMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2020-03-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-03-31 0001078799 MCOA:InvestmentMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-04-01 2020-06-30 0001078799 MCOA:InvestmentMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2020-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-06-30 0001078799 MCOA:InvestmentMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-07-01 2020-09-30 0001078799 MCOA:InvestmentMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2020-09-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-09-30 0001078799 MCOA:InvestmentMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-10-01 2020-12-31 0001078799 MCOA:InvestmentMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2020-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2020-12-31 0001078799 MCOA:InvestmentMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2021-01-01 2021-03-31 0001078799 MCOA:InvestmentMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2021-03-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2021-03-31 0001078799 MCOA:InvestmentMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2021-04-01 2021-06-30 0001078799 MCOA:InvestmentMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2021-06-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2021-06-30 0001078799 MCOA:InvestmentMember 2021-07-01 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2021-07-01 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2021-07-01 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-07-01 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2021-07-01 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2021-07-01 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2021-07-01 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2021-07-01 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2021-07-01 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2021-07-01 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2021-07-01 2021-09-30 0001078799 MCOA:InvestmentMember 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2021-09-30 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2021-09-30 0001078799 MCOA:InvestmentMember 2021-10-01 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2021-10-01 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2021-10-01 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-10-01 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2021-10-01 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2021-10-01 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2021-10-01 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2021-10-01 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2021-10-01 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2021-10-01 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2021-10-01 2021-12-31 0001078799 MCOA:InvestmentMember 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:ConsolidatedEliminationsMember 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:CannabisGlobalMember 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:ECOXMember 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:CdistroMember 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:HempsmartBrazilMember 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:LynwoodJVMember 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:NaturalPlantExtractMember 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:SalinasVenturesMember 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:VBFBrandsMember 2021-12-31 0001078799 MCOA:InvestmentMember MCOA:VivabudsMember 2021-12-31 0001078799 MCOA:LoanPayableMember 2018-12-31 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2018-12-31 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2018-12-31 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2018-12-31 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2018-12-31 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2018-12-31 0001078799 MCOA:LoanPayableMember 2019-01-01 2019-03-31 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2019-01-01 2019-03-31 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2019-01-01 2019-03-31 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2019-01-01 2019-03-31 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2019-01-01 2019-03-31 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2019-01-01 2019-03-31 0001078799 MCOA:LoanPayableMember 2019-03-31 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2019-03-31 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2019-03-31 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2019-03-31 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2019-03-31 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2019-03-31 0001078799 MCOA:LoanPayableMember 2019-04-01 2019-06-30 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2019-04-01 2019-06-30 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2019-04-01 2019-06-30 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2019-04-01 2019-06-30 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2019-04-01 2019-06-30 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2019-04-01 2019-06-30 0001078799 MCOA:LoanPayableMember 2019-06-30 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2019-06-30 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2019-06-30 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2019-06-30 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2019-06-30 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2019-06-30 0001078799 MCOA:LoanPayableMember 2019-07-01 2019-09-30 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2019-07-01 2019-09-30 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2019-07-01 2019-09-30 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2019-07-01 2019-09-30 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2019-07-01 2019-09-30 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2019-07-01 2019-09-30 0001078799 MCOA:LoanPayableMember 2019-09-30 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2019-09-30 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2019-09-30 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2019-09-30 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2019-09-30 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2019-09-30 0001078799 MCOA:LoanPayableMember 2019-10-01 2019-12-31 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2019-10-01 2019-12-31 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2019-10-01 2019-12-31 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2019-10-01 2019-12-31 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2019-10-01 2019-12-31 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2019-10-01 2019-12-31 0001078799 MCOA:LoanPayableMember 2019-12-31 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2019-12-31 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2019-12-31 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2019-12-31 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2019-12-31 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2019-12-31 0001078799 MCOA:LoanPayableMember 2020-01-01 2020-03-31 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2020-01-01 2020-03-31 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2020-01-01 2020-03-31 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2020-01-01 2020-03-31 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2020-01-01 2020-03-31 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2020-01-01 2020-03-31 0001078799 MCOA:LoanPayableMember 2020-03-31 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2020-03-31 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2020-03-31 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2020-03-31 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2020-03-31 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2020-03-31 0001078799 MCOA:LoanPayableMember 2020-04-01 2020-06-30 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2020-04-01 2020-06-30 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2020-04-01 2020-06-30 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2020-04-01 2020-06-30 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2020-04-01 2020-06-30 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2020-04-01 2020-06-30 0001078799 MCOA:LoanPayableMember 2020-06-30 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2020-06-30 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2020-06-30 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2020-06-30 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2020-06-30 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2020-06-30 0001078799 MCOA:LoanPayableMember 2020-07-01 2020-09-30 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2020-07-01 2020-09-30 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2020-07-01 2020-09-30 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2020-07-01 2020-09-30 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2020-07-01 2020-09-30 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2020-07-01 2020-09-30 0001078799 MCOA:LoanPayableMember 2020-09-30 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2020-09-30 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2020-09-30 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2020-09-30 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2020-09-30 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2020-09-30 0001078799 MCOA:LoanPayableMember 2020-10-01 2020-12-31 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2020-10-01 2020-12-31 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2020-10-01 2020-12-31 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2020-10-01 2020-12-31 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2020-10-01 2020-12-31 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2020-10-01 2020-12-31 0001078799 MCOA:LoanPayableMember 2020-12-31 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2020-12-31 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2020-12-31 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2020-12-31 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2020-12-31 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2020-12-31 0001078799 MCOA:LoanPayableMember 2021-01-01 2021-03-31 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2021-01-01 2021-03-31 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2021-01-01 2021-03-31 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2021-01-01 2021-03-31 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2021-01-01 2021-03-31 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2021-01-01 2021-03-31 0001078799 MCOA:LoanPayableMember 2021-03-31 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2021-03-31 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2021-03-31 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2021-03-31 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2021-03-31 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2021-03-31 0001078799 MCOA:LoanPayableMember 2021-04-01 2021-06-30 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2021-04-01 2021-06-30 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2021-04-01 2021-06-30 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2021-04-01 2021-06-30 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2021-04-01 2021-06-30 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2021-04-01 2021-06-30 0001078799 MCOA:LoanPayableMember 2021-06-30 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2021-06-30 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2021-06-30 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2021-06-30 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2021-06-30 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2021-06-30 0001078799 MCOA:LoanPayableMember 2021-07-01 2021-09-30 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2021-07-01 2021-09-30 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2021-07-01 2021-09-30 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2021-07-01 2021-09-30 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2021-07-01 2021-09-30 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2021-07-01 2021-09-30 0001078799 MCOA:LoanPayableMember 2021-09-30 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2021-09-30 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2021-09-30 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2021-09-30 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2021-09-30 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2021-09-30 0001078799 MCOA:LoanPayableMember 2021-10-01 2021-12-31 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2021-10-01 2021-12-31 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2021-10-01 2021-12-31 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2021-10-01 2021-12-31 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2021-10-01 2021-12-31 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2021-10-01 2021-12-31 0001078799 MCOA:LoanPayableMember 2021-12-31 0001078799 MCOA:LoanPayableMember MCOA:NaturalPlantExtractMember 2021-12-31 0001078799 MCOA:LoanPayableMember MCOA:RobertLHymersIIIMember 2021-12-31 0001078799 MCOA:LoanPayableMember MCOA:VBFBrandsMember 2021-12-31 0001078799 MCOA:LoanPayableMember MCOA:VivabudsMember 2021-12-31 0001078799 MCOA:LoanPayableMember us-gaap:OperatingExpenseMember 2021-12-31 0001078799 2020-06-30 0001078799 2020-03-31 0001078799 2019-09-30 0001078799 2019-06-30 0001078799 2019-03-31 0001078799 2018-12-31 0001078799 us-gaap:CommonStockMember MCOA:SettlementForConvertibleNotesMember 2021-01-01 2021-12-31 0001078799 us-gaap:CommonStockMember MCOA:SettlementForConvertibleNotesMember 2020-01-01 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableOneMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0001078799 MCOA:ConvertibleNotesPayableOneMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableFromJulyOneToSeptemberTwelveTwoThousandNineteenMember 2019-09-12 0001078799 MCOA:ConvertibleNotesPayableFromOctoberOneToDecemberThirtyOneTwoThousandNineteenMember 2021-01-01 2021-12-31 0001078799 MCOA:ConvertibleNotesPayableFromJulyOneToSeptemberTwelveTwoThousandNineteenMember 2021-12-31 0001078799 MCOA:ConvertibleNotesPayableFromOctoberOneToDecemberThirtyOneTwoThousandNineteenMember 2021-12-31 0001078799 MCOA:ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember 2019-12-19 0001078799 MCOA:ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember 2021-12-31 0001078799 MCOA:ConvertibleNotesPayableDecemberNineteenTwoThousandNineteenMember 2020-09-30 0001078799 MCOA:ConvertibleNotePayableGSCapitalPartnersLLCMember 2021-08-31 0001078799 MCOA:ConvertiblesNotesPayableDecemberNineteenTwoThousandNineteenMember 2021-12-31 0001078799 MCOA:TwoConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember 2021-10-06 0001078799 MCOA:TwoConvertibleNotesPayableJanuaryTwentyNineTwoThousandNineteenMember 2021-01-01 2021-12-31 0001078799 MCOA:BucktownCapitalLLCMember 2021-03-01 2021-03-31 0001078799 MCOA:SecuredConvertiblePromissoryNoteMember 2021-10-01 2021-10-06 0001078799 MCOA:SecuredConvertiblePromissoryNoteMember 2021-10-06 0001078799 MCOA:SecuredConvertiblePromissoryNoteMember 2021-12-31 0001078799 MCOA:ConvertibleNotesPayableSeptemberEightTwoThousandTwentyMember 2020-06-17 0001078799 MCOA:ConvertibleNotesPayableSeptemberEightTwoThousandTwentyMember 2020-09-08 0001078799 MCOA:ConvertibleNotesPayableRobertLHymersIIIMember 2021-02-04 0001078799 MCOA:PinnacleConsultingServicesIncMember 2021-04-30 0001078799 MCOA:PinnacleConsultingServicesIncMember 2021-12-27 0001078799 MCOA:PinnacleConsultingServicesIncMember 2021-12-31 0001078799 MCOA:NaturalPlantExtractMember 2020-02-01 2020-02-03 0001078799 srt:MaximumMember MCOA:NaturalPlantExtractMember 2020-02-03 0001078799 srt:MinimumMember MCOA:NaturalPlantExtractMember 2020-02-03 0001078799 MCOA:NaturalPlantExtractMember 2020-02-03 0001078799 MCOA:GWHoldingsGroupMember 2020-12-09 0001078799 MCOA:ConvertibleNotePayableGWHoldingsGroupMember 2021-06-03 0001078799 MCOA:ConvertibleNotePayableGWHoldingsGroupMember 2021-12-31 0001078799 MCOA:ConvertibleNotePayableGWHoldingsGroupMember 2021-08-24 0001078799 MCOA:RedstartHoldingsMember 2020-12-31 0001078799 MCOA:RedstartHoldingsMember 2021-03-31 0001078799 MCOA:RedstartHoldingsMember MCOA:ThreeConvertiblePromissoryNotesMember 2021-05-31 0001078799 MCOA:RedstartHoldingsMember 2021-12-31 0001078799 MCOA:RedstartHoldingsMember MCOA:ThreeConvertiblePromissoryNotesMember 2021-12-31 0001078799 MCOA:ConvertiblenotepayableFirstfireMember 2021-09-30 0001078799 MCOA:ConvertiblenotepayableFirstfireMember 2021-01-01 2021-09-30 0001078799 MCOA:ConvertiblenotepayableFirstfireMember 2021-12-31 0001078799 MCOA:ConvertiblenotepayableFirstfireMember 2021-01-01 2021-12-31 0001078799 MCOA:ConvertibleNotePayableLabrysMember 2021-12-31 0001078799 MCOA:LabrysMember 2021-12-31 0001078799 MCOA:LabrysMember 2021-01-01 2021-12-31 0001078799 MCOA:DutchessCapitalGrowthFundLPMember 2021-05-25 0001078799 MCOA:DutchessCapitalGrowthFundLPMember 2021-05-01 2021-05-25 0001078799 MCOA:DutchessCapitalGrowthFundLPMember 2021-12-31 0001078799 MCOA:GenevaRothHoldingsMember 2020-12-04 0001078799 MCOA:GenevaRothHoldingsMember 2021-07-28 0001078799 MCOA:GenevaRothHoldingsMember 2021-07-02 2021-07-28 0001078799 MCOA:GenevaRothHoldingsMember 2021-12-31 0001078799 MCOA:BeachLabsMember 2021-11-24 0001078799 MCOA:BeachLabsMember 2021-12-31 0001078799 MCOA:SixthStreetLendingMember 2021-11-16 0001078799 MCOA:SixthStreetLendingMember 2021-11-02 2021-11-16 0001078799 MCOA:SixthStreetLendingMember 2021-12-31 0001078799 MCOA:CoventryMember 2021-12-29 0001078799 MCOA:CoventryMember 2021-12-02 2021-12-29 0001078799 MCOA:CoventryMember 2021-12-31 0001078799 srt:MinimumMember 2021-01-01 2021-12-31 0001078799 srt:MaximumMember 2021-01-01 2021-12-31 0001078799 2020-04-01 2020-05-04 0001078799 MCOA:ConvertibleNotePayableElevenMember 2021-12-31 0001078799 MCOA:ConvertibleNotePayableElevenMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableTwelveMember 2021-12-31 0001078799 MCOA:ConvertibleNotePayableTwelveMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableLabrysMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableFFGlobalOpportunitiesFundMember 2021-12-31 0001078799 MCOA:ConvertibleNotePayableFFGlobalOpportunitiesFundMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableGSCapitalPartnersLLCMember 2021-12-31 0001078799 MCOA:ConvertibleNotePayableGSCapitalPartnersLLCMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableBeachLabsMember 2021-12-31 0001078799 MCOA:ConvertibleNotePayableBeachLabsMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayablePinnacleConsultingServicesIncMember 2021-12-31 0001078799 MCOA:ConvertibleNotePayablePinnacleConsultingServicesIncMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableGenevaRothMember 2021-12-31 0001078799 MCOA:ConvertibleNotePayableGenevaRothMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableDutchessCapitalPartnersMember 2021-12-31 0001078799 MCOA:ConvertibleNotePayableDutchessCapitalPartnersMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableRedstartHLDGSMember 2021-12-31 0001078799 MCOA:ConvertibleNotePayableRedstartHLDGSMember 2020-12-31 0001078799 MCOA:ConvertibleNotePayableGWHoldingsMember 2021-12-31 0001078799 MCOA:ConvertibleNotePayableGWHoldingsMember 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableCoventryMember 2021-12-31 0001078799 MCOA:ConvertibleNotesPayableCoventryMember 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableSixthStreetLendingMember 2021-12-31 0001078799 MCOA:ConvertibleNotesPayableSixthStreetLendingMember 2020-12-31 0001078799 MCOA:ConvertibleNotesPayableStGeorgeMember 2021-12-31 0001078799 MCOA:ConvertibleNotesPayableStGeorgeMember 2020-12-31 0001078799 us-gaap:PreferredClassBMember MCOA:JesusQuinteroMember 2020-11-09 0001078799 us-gaap:CommonStockMember MCOA:ServicesRenderedMember 2021-01-01 2021-12-31 0001078799 us-gaap:CommonStockMember MCOA:ConvertibleNotesPayableAndAccruedInterestMember 2021-01-01 2021-12-31 0001078799 us-gaap:CommonStockMember MCOA:RelatedPartyNotesPayableMember 2021-01-01 2021-12-31 0001078799 us-gaap:CommonStockMember MCOA:ExchangeForExerciseOfWarrantsMember 2021-01-01 2021-12-31 0001078799 us-gaap:CommonStockMember MCOA:CommonStockSharesSoldMember 2021-01-01 2021-12-31 0001078799 us-gaap:CommonStockMember us-gaap:ServiceMember 2020-01-01 2020-12-31 0001078799 us-gaap:CommonStockMember MCOA:ConvertibleNotesPayablesMember 2020-01-01 2020-12-31 0001078799 us-gaap:CommonStockMember MCOA:RelatedPartyMember MCOA:NotesPayableOtherPayablesTwoMember 2020-01-01 2020-12-31 0001078799 us-gaap:CommonStockMember us-gaap:WarrantMember 2020-01-01 2020-12-31 0001078799 us-gaap:WarrantMember 2019-12-31 0001078799 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001078799 us-gaap:WarrantMember 2020-12-31 0001078799 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001078799 us-gaap:WarrantMember 2021-12-31 0001078799 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001078799 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001078799 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001078799 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-12-31 0001078799 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001078799 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-12-31 0001078799 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001078799 srt:ChiefExecutiveOfficerMember us-gaap:PreferredClassBMember 2021-01-01 2021-12-31 0001078799 MCOA:LiabilitiesAndAccrualsMember 2021-12-31 0001078799 MCOA:LiabilitiesAndAccrualsMember 2020-12-31 0001078799 MCOA:LiabilitiesAndAccrualsMember MCOA:CdistroMember 2021-12-31 0001078799 MCOA:LiabilitiesAndAccrualsMember MCOA:CdistroMember 2020-12-31 0001078799 2020-05-04 0001078799 us-gaap:EmploymentContractsMember srt:ChiefExecutiveOfficerMember 2020-02-01 2020-02-03 0001078799 us-gaap:PreferredClassBMember MCOA:JesusQuinteroMember 2021-04-29 2021-05-02 0001078799 MCOA:MrQuinteroMember 2021-04-01 2021-04-27 0001078799 us-gaap:EmploymentContractsMember srt:ChiefExecutiveOfficerMember 2020-02-27 2020-02-28 0001078799 MCOA:CannabisGlobalIncMember 2020-09-01 2020-09-30 0001078799 MCOA:SubscriptionsPayableMember 2021-03-02 0001078799 MCOA:SubscriptionsPayableMember 2021-12-31 0001078799 MCOA:SubscriptionsPayableMember 2021-01-01 2021-12-31 0001078799 MCOA:CdistroMember 2021-06-01 2021-06-29 0001078799 2021-06-01 2021-06-29 0001078799 2021-06-29 0001078799 MCOA:MergerAgreementMember 2021-12-31 0001078799 MCOA:MergerAgreementMember 2021-01-01 2021-12-31 0001078799 2017-12-08 0001078799 2018-02-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

 

(Mark One)    

 

 

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Fiscal Year Ended December 31, 2021

 

Or

 

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period From                          to                     

 

 

Commission File Number 000-27039

MARIJUANA COMPANY OF AMERICA, INC.
(Exact name of registrant as specified in its charter)

     
Utah
(State or other jurisdiction of
incorporation or organization)
 

98-1246221

(I.R.S. Employer
Identification No.)

 

633 W. 5th Street, Suite 2826
Los Angeles, California 90071
(Address of principal executive offices)

 

 

92029
(Zip Code)

 

(888) 777-4362
(Registrant's telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

None

(Title of each class)

 

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.001 Par Value

[File No. 333-250887]
(Title of each class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes     No 🗷

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes      No 🗷

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes 🗷    No 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes 🗷    No 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K ((§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer  
Non-accelerated filer   Smaller reporting company
Emerging growth company      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes     No 🗷

 

The aggregate market value of the common stock held by non-affiliates, based upon the average bid and asked price of common stock, as of the last business day of the registrant’s most recently completed fiscal year was $6,858,930.

As of December 31, 2021, 7,122,806,264 shares of common stock were outstanding.

As of April 15, 2022, 10,152,014,210 shares of common stock were outstanding.

  

 

 
 
 

TABLE OF CONTENTS 

 

    Page
PART I
 
Item 1.   Business     4  
Item 1A.   Risk Factors     17  
Item 1B.   Unresolved Staff Comments     29  
Item 2.   Properties     29  
Item 3.   Legal Proceedings     29  
Item 4.   Mine Safety Disclosures     30  
             
PART II
 
Item 5.   Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities     31  
Item 6.   Selected Financial Data     32  
Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations     33  
Item 7A.   Quantitative and Qualitative Disclosure About Market Risk     48  
Item 8.   Financial Statements and Supplementary Data     49  
Item 9.   Changes In and Disagreements with Accountants on Accounting and Financial Disclosure     50  
Item 9A   Controls and Procedures     50  
Item 9B.   Other Information     51  
             
PART III
 
Item 10.   Directors, Executive Officers and Corporate Governance     52  
Item 11.   Executive Compensation     53  
Item 12.   Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters     54  
Item 13.   Certain Relationships and Related Transactions, and Director Independence     55  
Item 14.   Principal Accountant Fees and Services     55  
             
PART IV
 
Item 15.   Exhibits, Financial Statement Schedules     55  
Item 16.   Form 10-K Summary     55  

 

 

 

2  
 
 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K (this “Form 10-K”) includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. You should not place undue reliance on such statements because they are subject to numerous risks and uncertainties which are difficult to predict and many of which are beyond our control and could cause our actual results to differ from the forward-looking statements. Forward-looking statements include information concerning our possible or assumed future results of operations, including descriptions of our business strategy. These statements are often, but not always, made through the use of words or phrases such as “believe,” “anticipate,” “could,” “may,” “would,” “should,” “intend,” “plan,” “potential,” “predict,” “forecast,” “will,” “expect,” “budget,” “contemplate,” “believe,” “estimate,” “continue,” “project,” “positioned,” “strategy,” “outlook” and similar expressions. You should read statements that contain these words carefully because they:

 

discuss future expectations;
contain projections of future results of operations or financial condition; or
state other “forward-looking” information.

 

All such forward-looking statements are based on our current expectations and involve estimates and assumptions that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the results expressed in the statements. We believe it is important to communicate our expectations to our security holders. However, there may be future events that we are not able to predict accurately or over which we have no control. The risk factors and cautionary language discussed in this Form 10-K provide examples of risks, contingencies, uncertainties, and events that may cause our actual results to differ materially from the expectations described by us in such forward-looking statements, including among other things:

 

changes adversely affecting the industry in which we operate;
our ability to achieve our business strategies or to manage our growth;
general economic conditions, including the effects of COVID-19, the United Kingdom's exit from the European Union and the ongoing military conflict between Russia and Ukraine (and resulting sanctions) on the global economy, global financial markets and our business;
regional political and economic conditions, including emerging market conditions;
the effects of COVID-19 on supply and distribution chain, and the availability of third-party distributors generally;
the impact and magnitude of rising energy costs;
the impact and magnitude of inflation and currency fluctuations;
the regulation and legalization of adult-use, recreational cannabis;
our ability to maintain the listing of our securities on Nasdaq;
our ability to retain our key employees;
the availability or terms of future financing; and
other factors that are more fully discussed in Part I, Item 1A of this Form 10-K under the heading “Risk Factors” and elsewhere in this Form 10-K.

 

These risks could cause actual results to differ materially from those implied by the forward-looking statements contained in this Form 10-K.

 

All forward-looking statements included herein attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. These forward-looking statements speak only as of the date of this Form 10-K. Except to the extent required by applicable laws and regulations, we undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this Form 10-K or to reflect the occurrence of unanticipated events.

 

This Form 10-K contains estimates, projections and other information concerning our industry, our business, and the markets for our products. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.

 

3  
 
 

 

PART I.

 

Throughout this Annual Report on Form 10-K, references to “we,” “our,” “us,” the “Company,” or “Marijuana Company of America” refer to Marijuana Company of America, Inc., a corporation organized under the laws of Utah, individually, or as the context requires, collectively with its subsidiaries.

 

ITEM 1. BUSINESS

  

Our Mission

 

Our mission is to create value for our shareholders through innovation in the global hemp and cannabis industry. We strive to be an industry-leading global cannabis enterprise.

 

Overview

 

Marijuana Company of America is a Utah corporation quoted on OTC Markets Pink Tier under the symbol “MCOA”. We are based in Los Angeles, California.

 

We are an owner and operator of licensed cannabis cultivation, processing and dispensary facilities and a developer, producer and distributor of innovative branded cannabis and cannabidiol (“CBD”) products in the United States. We are committed to creating a national distributorship and retail brand portfolio of branded cannabis and CBD products, although as of the date of this filing, marijuana (defined as cannabis containing delta-9 tetrahydrocannabinol concentration of more than 0.3 percent on a dry weight basis) currently remains illegal under U.S. federal law.

 

Through our wholly-owned subsidiary cDistro, Inc., a Nevada corporation, our wholly-owned CBD product distribution business, we distribute hemp and CBD products throughout the United States. Through cDistro, we distribute high quality hemp-derived cannabinoid products, as detailed on our cDistro website, www.cdistro.com. cDistro offers CBD brands along with smoke and vape shop related products to wholesalers, c-stores, specialty retailers, and consumers in North America. Through cDistro, we work exclusively with select manufacturers to deliver retail service and products at wholesale prices

 

Through our wholly owned subsidiary HSmart, Inc., a California corporation, we develop and sell CBD products under the brand name hempSMART™. Our business also includes making selected investments and entering into joint ventures with start-up businesses in the legalized cannabis and hemp industries.

 

History and Development of the Company

 

We were incorporated in the State of Utah on October 4, 1985, under the name of Mormon Mint, Inc., and our business focused on the manufacture and marketing of commemorative medallions related to the Church of Jesus Christ of Latter-Day Saints. On January 5, 1999, the Company changed its name to Converge Global, Inc., and subsequently focused on the development and implementation of Internet web content and e-commerce applications. In the period from 2009 to 2014, we operated primarily in the mining exploration business, and in 2015, we left the mining business and began an internet-based marketing business focused on online marketing of service items to the hospitality and food service industry, selling retail product directly to consumers from food distributors via credit card and commercial accounts.

 

On September 4, 2015, Donald Steinberg and Charles Larsen acquired control of the Company through the purchase of 400,000,000 shares of restricted common stock and 10,000,000 shares of Preferred Class A stock for $105,000.00, in equal amounts. On September 9, 2015, Donald Steinberg was appointed Chairman of the Board, Chief Executive Officer and Secretary of the Company. Mr. Larsen was appointed to the Board of Directors. The new management changed the Company’s business plans and operations to focus on emerging opportunities in the cannabis and hemp industries. On December 1, 2015, the Company changed its name to Marijuana Company of America, Inc. and its stock trading symbol to MCOA. On December 6, 2019, a change of control occurred, where Donald Steinberg and Charles Larsen transferred their control shares to directors Robert Coale, Edward Manolos and Jesus Quintero. Also on December 6, 2019, Jesus Quintero, who was appointed as Chief Financial Officer in 2018, was appointed as our Chief Executive Officer. Mr. Quintero is currently our Chief Executive Officer and Chief Financial Officer, and a member of the Board of Directors.

 

4  
 
 

Operations

  

Distribution - cDistro, Inc. Through our wholly-owned subsidiary cDistro, Inc., a Nevada corporation, we distribute hemp and CBD products throughout the United States. We acquired the business and stock of cDistro on June 29, 2021, and the company is run by its founding partner and Chief Executive Officer, Ronald Russo, with our Chief Financial Officer. Through cDistro, we distribute high quality hemp-derived cannabinoid products, as detailed on our cDistro website, www.cdistro.com. cDistro offers CBD brands along with smoke and vape shop related products to wholesalers, c-stores, specialty retailers, and consumers in North America. Through cDistro, we work exclusively with select manufacturers to deliver retail service and products at wholesale prices.

 

At its website www.cdistro.com, cDistro distributes a select list of quality CBD brands along with smoke and vape shop related products to wholesalers, c-stores, specialty retailers, and dispensaries in North America. Founded in Florida in 2020 by Ronald Russo, cDistro distributes a catalog of unique product lines currently being sold to over 250 smoke and vape shop customers. Through our acquisition of cDistro, we believe MCOA is positioned to take advantage of the developing market opportunity generated by consumers' growing demand for quality hemp products.

 

hempSMART™

 

Our consumer products containing hemp and CBD are sold through our wholly owned subsidiary H Smart, Inc. under the brand name hempSMART™. We market and sell our hempSMART™ products directly through our web site, and through our affiliate marketing program, where qualified sales affiliates use a secure multi-level-marketing sales software program that facilitates order placement over the internet via a web site, and accounts for affiliate orders and sales; calculates referral benefits apportionable to specific sales associates and calculates and accounts for loyalty and rewards benefits for returning customers. The Company plans on focusing its sales and marketing through direct sales on its website and intends to wind down and terminate its affiliate marketing and sales program during fiscal 2021.

 

Our current hempSMART™ wellness products offerings include the following:

 

hempSMART Brain™ a proprietary patented and formulated personal care consumer product encapsulated with enriched non-psychoactive industrial hemp derived CBD. This encapsulation is combined with other high quality, proprietary natural ingredients to compliment CBD to support brain wellness.
hempSMART Pain™ capsules formulated with 10mg of Full Spectrum, non-psychoactive CBD per serving, derived from industrial hemp, which along with a proprietary blend of other natural ingredients, delivers an all-natural formulation for the temporary relief of minor discomfort associated with physical activity.
hempSMART Pain Cream™ each container formulated with 300mg of full spectrum non-psychoactive CBD derived from industrial hemp. The newly developed product contains a synergistic combination of natural botanicals and full spectrum hemp extract featuring CBD, CBG and a broad range of terpenes. The Company’s proprietary blend of Ayurvedic herbs along with Menthol, Cayenne Pepper Extract, Rosemary Oil, Aloe Gel, White Willow Bark, Arnica, Wintergreen Extract and Tea Tree Oil, provides an immediate cooling and soothing sensation. This topical wellness consumer product is formulated to help reduce minor discomfort and promote muscle relaxation on areas that it is applied.
hempSMART Drops™ full Spectrum Hemp CBD Oil Tincture Drops, available in 250mg and 500mg bottles, enriched with non-psychoactive industrial hemp derived CBD, and available in four different flavors: lemon, mint, orange and strawberry that is free of the THC isolate. 
hempSMART Pet Drops™ for cats and dogs, formulated with 250mg of full spectrum non-psychoactive CBD derived from industrial hemp. This new specially formulated product contains naturally occurring CBD derived from hemp seed oil, full spectrum hemp extract, fractionated coconut oil, and a rich bacon flavor.
hempSMART Face™ a nourishing facial moisturizer combines full spectrum CBD from hemp, with a unique blend of Ayurvedic herbs and botanicals. Designed to refresh, replenish and restore the skin providing long lasting hydration and balance.
hempSMART Drink Mix, a new industrial hemp based powderized premium CBD Drink made with Organic CBD Infused with Honey to be mixed with any beverage of preference.

 

5  
 
 

Growth Strategies and Strategic Priorities

 

Recent Acquisition

 

cDistro, Inc.

 

On June 29, 2021, we acquired 100% of the capital stock of cDistro, Inc., a Florida-based hemp and CBD product distribution business incorporated in the State of Nevada (“cDistro”) by a statutory merger and share exchange. After the acquisition, cDistro’s founding partner and Chief Executive Officer, Ronald Russo, remains its Chief Executive Officer, and our Chief Financial Officer Jesus Quintero serves as cDistro’s Chief Financial Officer.

 

VBF Brands, Inc.

 

On October 6, 2021, the Company, through its wholly owned subsidiary Salinas Diversified Ventures, Inc., a California corporation, entered into an Asset Purchase Agreement, Management Services Agreement, Cooperation Agreement and Employment Agreement with VBF Brands, Inc., a California corporation (“VBF”), a wholly owned subsidiary of Sunset Island Group, Inc., a Colorado corporation (“SIGO”). VBF and SIGO agreed to transfer to the Company all of VBF’s outstanding stock to the Company, and appointed our CEO and CFO Jesus Quintero as President of VBF.

 

VBF owns various fixed assets including machinery and equipment, a lease for a 10,000 square foot facility located at 20420 Spence Road, Salinas, California, 93908, leasehold improvements, good-will, inventory, tradenames including “VBF Brands,” trade secrets, intellectual property, and other tangible and intangible properties, including licenses issued by the City of Salinas, County of Monterey, and the State of California to operate a licensed cannabis nursery, cultivation facility, and operations for the manufacturing and distribution of cannabis and cannabis products.

 

VBF and SIGO agreed to sell and transfer to the Company all of VBF’s outstanding stock, and, by virtue of the Management Services Agreement, appoint Mr. Jesus Quintero as President of VBF, vesting management and control of VBF’s licensed cannabis operations in the Company. Concurrently, VBF and Livacich entered into a Cooperation Agreement, whereby VBF and Livacich agreed to cooperate to facilitate the transfer of ownership of VBF, which includes licenses issued by the City of Salinas, County of Monterey, and the State of California, to operate a cannabis nursery, cultivation facility and manufacturing and distribution operations to the Company. The Company also agreed to retain Livacich as Chief Executive Officer for a term of two years and agreed to compensate her with a salary including a signing cash bonus of $250,000, and a $250,000 performance cash bonus payable after six months after the Effective Date. The bonus is conditioned upon Livacich meeting an agreed to “Net Revenue” target of one million dollars ($1,000,000) from VBF’s operations during the six-month period after closing of the Asset Purchase Agreement, and her compliance with the terms and conditions of this Asset Purchase Agreement, the Management Services Agreement and the Cooperation Agreement.

 

As consideration for the transaction, the Company agreed to assume two secured convertible promissory notes issued by SIGO to St. George Investments, LLC, a Utah limited liability company (“St. George”) (the “SIGO Notes”). The first note was issued December 8, 2017, in the original face amount of $170,000.00, and the second was issued February 13, 2018, in the original face amount of $4,245,000.00. SIGO also issued warrants to St. George to purchase shares in SIGO, and fifty (50) shares of Series A Preferred Stock in SIGO. St. George agreed to cancel the warrants and preferred shares upon the Company’s assumption of the SIGO Notes.

 

Under the Asset Purchase Agreement, the closing is conditioned upon certain conditions precedent, specifically (i) VBF and SIGO’s full corporate authorization, consent and execution of this Agreement; (ii) VBF’s sale to MCOA of 100% of the issued and outstanding shares of VBF; (iii) full corporate authorization, consent compliance with and execution of the Management Services Agreement and Cooperation Agreement; (iv) SIGO’s disclosure of the Agreement on Form 8-K with the Securities and Exchange Commission; (v) full cooperation in MCOA’s financial auditing of VBF in accordance with ASC 805, including providing unrestricted access to all VBF corporate and financial records and providing all necessary cooperation with VBF financial personnel; (vi) full cooperation in aiding and assisting Buyer with its change of ownership applications with the relevant licensing authorities; (vii) the warranty of truthful representations and execution of and compliance with the terms and conditions of the Executive Employment Agreement, Management Services Agreement and the Cooperation Agreement.

 

As of the date of this filing, the conditions precedent to the closing of the Asset Purchase Agreement remain in the process of implementation, so that the Asset Purchase Agreement closing has not yet occurred pursuant to its terms. Legal counsel for MCOA is currently in the process of working with VBF, Salinas Diversified Ventures, and the relevant state and local governments to effect the change of control and license transfers necessary to close the Asset Purchase Agreement. The audit of VBF is also underway and the Company expects to finalize it soon.

 

6  
 
 

Competition

 

Our competitors include sellers of hemp-based CBD products and professional services firms dedicated to the regulated hemp industry. We compete in markets where hemp has been legalized and regulated, which includes the United States, Canada and the United Kingdom. Our marketing efforts in Brazil and Uruguay are in the development stages. We expect that the quantity and composition of our competitive environment will continue to evolve as the global industry matures. Additionally, increased competition worldwide is possible to the extent that new states, jurisdictions and countries enter the marketplace as a result of continued enactment of regulatory and legislative changes that de-criminalize and regulate hemp products, including the 2018 Farm Bill. We believe that by being well established in the industry, along with our experience, and our continued expansion of service and product offerings in new and existing locations, are factors that mitigate the risks associated with operating in a developing competitive environment. Additionally, the contemporaneous growth of the industry as a whole will result in new customers entering the marketplace, thereby further mitigating the impact of competition on our expected operations and results.

 

Joint Ventures and Investments

 

Our business also includes participating and making selected investments in other related businesses. The following disclosures include two parts. The first part discloses past joint ventures and investments that as of December 31, 2021 and 2020, were no longer effective and do not have a material current effect on the Company or its financial condition. These disclosures are provided to give a historical account of joint venture and investment activity over the past three to four years. The second part discloses active joint ventures and investments having a material effect on current operations and financial condition.

 

1. Past Joint Ventures & Investments

  

Viva Buds Joint Venture with Natural Plant Extracts of California Inc.; On April 15, 2019, the Company entered into a joint venture agreement with Natural Plant Extracts of California, Inc. and subsidiaries (“NPE”). The purpose of the joint venture was to utilize NPE’s California and City cannabis licenses to jointly operate a business named “Viva Buds” to operate a licensed cannabis distribution service in California. In exchange for acquiring 20% of NPE’s common stock, the Company agree to pay two million dollars and issue NPE one million dollars’ worth of the Company’s restricted common stock. As of February 3, 2020, the Company was in arrears in its payment obligations under the joint venture agreement, and the parties entered into a settlement and release of all claims terminating the joint venture. The parties agreed to reduce the Company’s equity ownership in NPE from 20% to 5%. The Company also agreed to pay NPE $85,000 and the balance of $56,085.15 paid in a convertible promissory note issued with terms allowing NPE to convert the note into common stock at a 50% discount to the closing price of MCOA’s common stock as of the maturity date. As of the date of this filing, the Company satisfied its payment obligations under the settlement agreement. Our continuing 5% equity ownership in NPE involves related parties, since Edward Manolos, our director, is also a director and shareholder of Cannabis Global, Inc., which is the controlling shareholder holding 55% of Natural Plant Extract of California Inc.

 

 

Natural Plant Extract of California & Subsidiaries Joint Venture; On April 15, 2019, the Company entered into a joint venture agreement with Natural Plant Extracts of California, Inc. and subsidiaries. The purpose of the joint venture was to utilize Natural Plant Extracts’ California and City cannabis licenses to jointly operate a business named “Viva Buds” to operate a licensed cannabis distribution service in California. In exchange for acquiring 20% of Natural Plant Extracts’ common stock, the Company agree to pay two million dollars and issue Natural Plant Extract one million dollars’ worth of the Company’s restricted common stock. As of February 3, 2020, the Company was in arrears in its payment obligations under the joint venture agreement, and the parties entered into a settlement and release of all claims terminating the joint venture. The parties agreed to reduce the Company’s equity ownership in Natural Plant Extracts from 20% to 5%. The Company also agreed to pay Natural Plant Extracts $85,000 and the balance of $56,085.15 paid in a convertible promissory note issued with terms allowing Natural Plant Extracts to convert the note into common stock at a 50% discount to the closing price of MCOA’s common stock as of the maturity date. As of the date of this filing, the Company satisfied its payment obligations under the settlement agreement

 

7  
 
 

2. Current Joint Ventures  and Investments.

 

Global Hemp Group Joint Venture/Scio Oregon Hemp Project; On May 8, 2018, the Company, Global Hemp Group, Inc., a Canadian corporation, and TTO Enterprises, Ltd., an Oregon corporation entered into a Joint Venture Agreement. The purpose of the joint venture is to develop a project to commercialize the cultivation of industrial hemp on a 109 acre parcel of real property owned by the Company and Global Hemp Group in Scio, Oregon, and operating under the Oregon corporation Covered Bridges, Ltd. The joint venture agreement committed the Company to provide cash contributions of $600,000 payable on the following funding schedule: $200,000 upon execution of the joint venture agreement; $238,780 by July 31, 2018; $126,445 by October 31, 2018; and, $34,775 by January 31, 2019. The Company complied with its payments. The 2018 crop of hemp grown on the joint venture’s real property consisted of 33 acres of high yielding CBD hemp grown in an orchard style cultivation on the property. The 2018 harvest consisted of approximately 37,000 high yielding CBD hemp plants producing 24 tons of biomass that produced 48,000 pounds of dried biomass. The joint venture partners prepared processing samples ranging in size from 100 lbs. to 2,000 lbs. for sample offers to extraction companies. However, there were delays with Global Hemp Group’s management and maintenance of the business and the biomass that caused degradation to the harvested crop affecting marketability. Additional issues and disputes arose between the Company and Global Hemp Group. These disputes led to the parties entering into a settlement agreement on September 28, 2020, whereby Global Hemp Group agreed to pay the Company $200,000 and issue common stock to the Company equal in value to $185,000 as of September 28, 2020, subject to a non-dilutive protection provision. Additionally, Global Hemp Group agreed to pay the Company $10,000 to cover the Company’s legal fees relating to the Agreement. In exchange for the settlement consideration, the Company agreed to relinquish its ownership interest in the joint venture.

 

Bougainville Ventures, Inc. Joint Venture; On March 16, 2017, we entered into a joint venture agreement with Bougainville Ventures, Inc., a Canadian corporation. The purpose of the joint venture was for the Company and Bougainville to (i) jointly engage in the development and promotion of products in the legalized cannabis industry in Washington State; (ii) utilize Bougainville's high quality cannabis grow operations in the State of Washington, where it claimed to have an ownership interest in real property for use within the legalized cannabis industry; (iii) leverage Bougainville’s agreement with a I502 Tier 3 license holder to grow cannabis on the site; provide technical and management services and resources including, but not limited to: sales and marketing, agricultural procedures, operations, security and monitoring, processing and delivery, branding, capital resources and financial management; and, (iv) optimize collaborative business opportunities. The Company and Bougainville agreed to operate through a Washington State Limited Liability Company, and BV-MCOA Management, LLC was organized in the State of Washington on May 16, 2017.

 

As our contribution to the joint venture, the Company committed to raise not less than $1,000,000 to fund joint venture operations, based upon a funding schedule. The Company also committed to providing branding and systems for the representation of cannabis related products and derivatives comprised of management, marketing and various proprietary methodologies directly tailored to the cannabis industry.

The Company and Bougainville's agreement provided that funding by the Company would pay for the joint venture’s ultimate purchase of the land consisting of a one-acre parcel located in Okanogan County, Washington, for joint venture operations.

 

As disclosed on Form 8-K on December 11, 2017, the Company did not comply with the funding schedule for the joint venture. On November 6, 2017, the Company and Bougainville amended the joint venture agreement to reduce the amount of the Company's commitment from $1,000,000 to $800,000, and also required the Company to issue Bougainville 15 million shares of the Company's restricted common stock. The Company completed its payments pursuant to the amended agreement on November 7, 2017, and on November 9, 2017, issued to Bougainville 15 million shares of restricted common stock. The amended agreement provided that Bougainville would deed the real property to the joint venture within thirty days of its receipt of payment.

8  
 
 

Thereafter, the Company determined that Bougainville had no ownership interest in the property in Washington State, but rather was a party to a purchase agreement for real property that was in breach of contract for non-payment. Bougainville also did not possess an agreement with a Tier 3 I502 license holder to grow Marijuana on the property. Nonetheless, as a result of funding arranged for by the Company, Bougainville and an unrelated third party, Green Ventures Capital Corp., purchased the land, but did not deed the real property to the joint venture. Bougainville failed to pay delinquent property taxes to Okanogan County and to date, the property has not been deeded to the joint venture.

 

To clarify the respective contributions and roles of the parties, the Company offered to enter into good faith negotiations to revise and restate the joint venture agreement with Bougainville. The Company diligently attempted to communicate with Bougainville to accomplish a revised and restated joint venture agreement, and efforts towards satisfying the conditions to complete the subdivision of the land by the Okanogan County Assessor. However, Bougainville failed to cooperate or communicate with the Company in good faith, and failed to pay the delinquent taxes on the real property that would allow for sub-division and the deeding of the real property to the joint venture.

 

On August 10, 2018, the Company advised its independent auditor that Bougainville did not cooperate or communicate with the Company regarding its requests for information concerning the audit of Bougainville’s receipt and expenditures of $800,000 contributed by the Company in the joint venture agreement. Bougainville had a material obligation to do so under the joint venture agreement. The Company believes that some of the funds it paid to Bougainville were misappropriated and that there was self-dealing with respect to those funds. Additionally, the Company believes that Bougainville misrepresented material facts in the joint venture agreement, as amended, including, but not limited to, Bougainville’s representations that: (i) it had an ownership interest in real property that was to be deeded to the joint venture; (ii) it had an agreement with a Tier 3 # I502 cannabis license holder to grow cannabis on the real property; and, (iii) that clear title to the real property associated with the Tier 3 # I502 license would be deeded to the joint venture thirty days after the Company made its final funding contribution. As a result, on September 20, 2018, the Company filed suit against Bougainville Ventures, Inc., BV-MCOA Management, LLC, Andy Jagpal, Richard Cindric, et al. in Okanogan County Washington Superior Court, case number 18-2- 0045324. The Company’s complaint seeks legal and equitable relief for breach of contract, fraud, breach of fiduciary duty, conversion, recession of the joint venture agreement, an accounting, quiet title to real property in the name of the Company, for the appointment of a receiver, the return to treasury of 15 million shares issued to Bougainville, and, for treble damages pursuant to the Consumer Protection Act in Washington State. The registrant has filed a lis pendens on the real property. The case is currently in litigation.

 

In connection with the agreement, the Company recorded a cash investment of $1,188,500 to the Joint Venture during 2017. This was comprised of 49.5% ownership of BV-MCOA Management LLC, and was accounted for using the equity method of accounting. The Company recorded an annual impairment in 2017 of $792,500, reflecting the Company’s percentage of ownership of the net book value of the investment. During 2018, the Company recorded equity losses of $37,673 and $11,043 for the first and second quarters respectively, and recorded an annual impairment of $285,986 for the year ended December 31, 2018, at which time the Company determined the investment to be fully impaired due to Bougainville’s breach of contract and resulting litigation, as discussed above.

 

 

Share Exchange with Cannabis Global, Inc. On September 30, 2020, the Company entered into a securities exchange agreement with Cannabis  Global, Inc., a Nevada corporation. By virtue of the agreement, the Company issued 650,000,000 shares of its unregistered common stock to Cannabis Global in exchange for 7,222,222 shares of Cannabis Global unregistered common stock. The Company and Cannabis Global also entered into a lock up leak out agreement which prevents either party from sales of the exchanged shares for a period of 12 months. Thereafter the parties may sell not more than the quantity of shares equaling an aggregate maximum sale value of $20,000 per week, or $80,000 per month until all Shares and Exchange Shares are sold. This material transaction involves related parties, insofar as Edward Manolos, our director, is also a director of Cannabis Global, Inc. 

 

 

9  
 
 

 

   

Share Exchange with Eco Innovation Group, Inc. On February 26, 2021, we entered into a Share Exchange Agreement with Eco Innovation Group, Inc., a Nevada corporation quoted on OTC Markets Pink (“ECOX”) to acquire the number of shares of ECOX’s common stock, equal in value to $650,000 based on the per-share price of $0.06, in exchange for the number of shares of MCOA common stock equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date (the “Share Exchange Agreement”).  For both parties, the Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the Share Exchange Agreement to fall below $650,000.

 

Complementary to the Share Exchange Agreement, the Company and ECOX entered into a Lock-Up Agreement dated February 26, 2021 (the “Lock-Up Agreement”), providing that the shares of common stock acquired pursuant to the Share Exchange Agreement shall be subject to a lock-up period preventing its sale for a period of 12 months following issuance and limiting the subsequent sale to aggregate maximum sale value of $20,000 per week, or $80,000 per month.

 

On October 1, 2021, we entered into a First Amendment to Lock-Up Agreement between the Company and Eco Innovation Group, Inc., dated and effective October 1, 2021 (the “Amended Lock-Up Agreement”), which amends that certain Lock-Up Agreement entered into between the Company and Eco Innovation Group, Inc. on February 26, 2021 (the “Original Lock-Up Agreement”). The Amended Lock-Up Agreement amends the Original Lock-Up Agreement in one respect, by amending the initial lock-up period from 12 months following its effective date to 6 months following its effective date. All other terms and conditions of the Original Lock-Up Agreement remain unaffected.

 

 

Government Regulation of Cannabis

 

Cannabis

 

In the United States, the cultivation, manufacturing, importation, distribution, use and possession of cannabis containing a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis is illegal under U.S. federal law. However, medical and adult-use cannabis has been legalized and regulated by individual states. Currently, 37 states plus the District of Columbia and certain U.S. territories recognize, in one form or another, the medical use of cannabis, while 18 of those states plus the District of Columbia and certain U.S. territories recognize, in one form or another, the full adult use of cannabis. Notwithstanding the regulatory environment with respect to cannabis at the state level, cannabis continues to be categorized as a Schedule I controlled substance under the CSA. Accordingly, the use, possession, or distribution of cannabis violates U.S. federal law. As a result, cannabis businesses in the United States are subject to inconsistent state and federal legislation, regulation and enforcement.

 

Under former President Barack Obama, in an effort to provide guidance to U.S. federal law enforcement regarding the inconsistent regulation of cannabis at the U.S. federal and state levels, the U.S. Department of Justice (“DOJ”) released a memorandum on August 29, 2013 titled “Guidance Regarding Marijuana Enforcement” from former Deputy Attorney General James Cole (the “Cole Memorandum”). The Cole Memorandum acknowledged that, although cannabis is a Schedule I controlled substance under the CSA, the U.S. Attorneys in states that have legalized cannabis should prioritize the use of the U.S. federal government’s limited prosecutorial resources by focusing enforcement actions on the following eight areas of concern (the “Cole Priorities”):

 

    Preventing the distribution of marijuana to minors;

 

    Preventing revenue from the sale of marijuana from going to criminal enterprises, gangs and cartels;

 

    Preventing the diversion of marijuana from states where it is legal under state law in some form to other states;

 

    Preventing state-authorized marijuana activity from being used as a cover or pretext for the trafficking of other illegal drugs or other illegal activity;

 

    Preventing violence and the use of firearms in the cultivation and distribution of marijuana;

 

    Preventing drugged driving and the exacerbation of other adverse public health consequences associated with marijuana use;

 

    Preventing the growing of marijuana on public lands and the attendant public safety and environmental dangers posed by marijuana production on public lands; and

 

    Preventing marijuana possession or use on U.S. federal property.

 

10  
 
 

In January 2018, under the administration of former President Donald Trump, former U.S. Attorney General Jeff Sessions rescinded the Cole Memorandum. While this did not create a change in U.S. federal law, as the Cole Memorandum was policy guidance and not law, the rescission added to the uncertainty of U.S. federal enforcement of the CSA in states where cannabis use is legal and regulated. Former Attorney General Sessions, concurrent with the rescission of the Cole Memorandum, issued a memorandum (“Sessions Memorandum”) which explained that the Cole Memorandum was “unnecessary” due to existing general enforcement guidance adopted in the 1980s, as set forth in the U.S. Attorney’s Manual (“USAM”). The USAM enforcement priorities, like those of the Cole Memorandum, are also based on the U.S. federal government’s limited resources and include law enforcement priorities set by the Attorney General, the seriousness of the alleged crimes, the deterrent effect of criminal prosecution and the cumulative impact of particular crimes on the community.

 

While the Sessions Memorandum emphasizes that cannabis is a Schedule I controlled substance under the CSA and states that it is a “dangerous drug and that marijuana activity is a serious crime,” it does not otherwise provide that the prosecution of cannabis-related offenses is now a DOJ priority. Furthermore, the Sessions Memorandum explicitly indicates that it is a guide for prosecutorial discretion and that discretion is firmly in the hands of U.S. Attorneys who determine whether to prosecute cannabis-related offenses. U.S. Attorneys could individually continue to exercise their discretion in a manner similar to that permitted under the Cole Memorandum. While certain U.S. Attorneys have publicly affirmed their commitment to proceeding in a manner contemplated under the Cole Memorandum, or otherwise affirmed that their views of U.S. federal enforcement priorities have not changed as a result of the rescission of the Cole Memorandum, others have publicly supported the rescission of the Cole Memorandum.

 

Under former Attorney General William Barr, the Department of Justice did not take a formal position on the federal enforcement of laws relating to cannabis. However, prior to his resignation on December 23, 2020, former Attorney General William Barr stated that his preference would be to have a uniform federal rule against cannabis, but, absent such a uniform rule, his preference would be to permit the existing federal approach leaving it up to the states to make their own decision. In addition, former Attorney General William Barr indicated that the DOJ was reviewing the Strengthening the Tenth Amendment Through Entrusting States Act (“STATES Act”), which would shield individuals and businesses complying with state cannabis laws from federal intervention.

 

On March 10, 2021, the Senate confirmed, President Joseph R. Biden’s nominee, Merrick Garland, to serve as Attorney General in his administration. Furthermore, two of President Biden’s nominees for top positions at the U.S. Department of Health and Human Services (“HHS”) have strong track records of supporting and defending state-legalized marijuana programs. California’s former Attorney General Xavier Becerra, who serves as the head of HHS, vowed to defend California’s legal cannabis market from any potential intervention during the Trump administration. In addition, Pennsylvania’s former Secretary of Health Dr. Rachel Levine, who serves as the Assistant Secretary of HHS, played a pivotal role in the implementation of Pennsylvania’s medical marijuana program. In addition, Democrats are generally more supportive of federal cannabis reform than Republicans. Currently, the Democrats compose a majority of the House of Representatives and have gained sufficient seats in the Senate to achieve control in the event of a Vice Presidential tie-breaking vote. Most notably, during the presidential campaign, President Biden stated that he supports decriminalizing marijuana. Despite the growing enthusiasm in the cannabis business community, it remains unclear whether the Department of Justice under President Biden and Attorney General Garland will re-adopt the Cole Memorandum or announce a substantive marijuana enforcement policy.

 

Other federal legislation provides or seeks to provide protection to individuals and businesses acting in violation of U.S. federal law but in compliance with state cannabis laws. For example, the Rohrabacher-Farr Amendment has been included in annual spending bills passed by Congress since 2014. The Rohrabacher-Farr Amendment restricts the DOJ from using federal funds to interfere with states implementing laws that authorize the use, distribution, possession, or cultivation of medical cannabis.

 

U.S. courts have construed these appropriations bills to prevent the U.S. federal government from prosecuting individuals or businesses engaged in cannabis-related activities to the extent they are operating in compliance with state medical cannabis laws. However, because this conduct continues to violate U.S. federal law, U.S. courts have observed that should the U.S. Congress choose to appropriate funds to prosecute individuals or businesses acting in violation of the CSA, such individuals or businesses could be prosecuted for violations of U.S. federal law even to the extent/even if they are operating in compliance with applicable state medical cannabis laws.

 

11  
 
 

If Congress declines to include the Rohrabacher-Farr Amendment in future fiscal year appropriations bills or fails to pass necessary budget legislation causing a government shutdown, the U.S. federal government will have the authority to spend federal funds to prosecute individuals and businesses acting contrary to the CSA for violations of U.S. federal law.

 

Furthermore, the appropriations protections only apply to individuals and businesses operating in compliance with a state’s medical cannabis laws and provide no protection to individuals or businesses operating in compliance with a state’s adult-use cannabis laws.

 

Additionally, there are a number of marijuana reform bills that have been introduced in the U.S. Congress that would amend federal law regarding the legal status and permissibility of medical and adult-use cannabis, including the STATES Act, the Marijuana Opportunity Reinvestment and Expungement Act (the “MORE Act”), the Substance Regulation and Safety Act (the “SRSA”) and the Medical Marijuana Research Act (the “MMRA”). The STATES Act would create an exemption in the CSA to allow states to determine their own cannabis policies without fear of federal reprisal.

 

The MORE Act, which was reintroduced to the House of Representatives on May 28, 2021, would remove cannabis from the CSA, expunge federal cannabis offenses and establish a 5% excise tax on cannabis to fund various federal grant programs. On March 1, 2022, the U.S. House of Representatives passed the MORE Act, a bill that would end the federal prohibition on cannabis by removing it from the list of banned controlled substances. This is the second time the bill passed the House; however, it is expected to receive opposition in the Senate and we have no clear expectation that the MORE Act will become law in the near future.

 

The SRSA, which was introduced by U.S. Senator Tina Smith on July 30, 2020, would remove cannabis from the CSA, grant the FDA authority to regulate cannabis and cannabis products and regulate the safety and quality control of cannabis crops and the import and export of cannabis materials. The MMRA, which was introduced in the House of Representatives on October 21, 2021, would amend the CSA to make marijuana accessible for use by qualified marijuana researchers for medical purposes. It is uncertain which federal marijuana reform bills, if any, will ultimately be passed and signed into law.

 

Businesses in the regulated cannabis industry, including our business, are subject to a variety of laws and regulations in the United States that involve money laundering, financial recordkeeping and proceeds of crime, including the U.S. Currency and Foreign Transactions Reporting Act of 1970 (“Bank Secrecy Act”) and the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act (the “US PATRIOT Act”) and the rules and regulations thereunder and any related or similar rules, regulations, or guidelines, issued, administered, or enforced by governmental authorities in the United States. Further, under U.S. federal law, banks or other financial institutions that provide a cannabis business with a checking account, debit or credit card, small business loan, or any other service could be charged with money laundering, aiding and abetting, or conspiracy.

 

Despite these laws, the Financial Crimes Enforcement Network (“FinCEN”), a bureau within the U.S. Department of the Treasury (“U.S. Treasury”), issued a memorandum on February 14, 2014 (the “FinCEN Memorandum”), which provides instructions to banks and other financial institutions seeking to provide services to cannabis-related businesses. The FinCEN Memorandum explicitly references the Cole Priorities and indicates that in some circumstances it is permissible for banks and other financial institutions to provide services to cannabis-related businesses without risking prosecution for violation of U.S. federal money laundering laws. Under these guidelines, financial institutions are subject to a requirement to submit a suspicious activity report in certain circumstances as required by federal money laundering laws. These cannabis-related suspicious activity reports are divided into three categories: marijuana limited, marijuana priority and marijuana terminated, based on the financial institution’s belief that the marijuana business follows state law, is operating out of compliance with state law, or where the banking relationship has been terminated, respectively. The FinCEN Memorandum refers to supplementary guidance in the Cole Memorandum relating to the prosecution of money laundering offenses predicated on cannabis-related violations of the CSA.

 

12  
 
 

The rescission of the Cole Memorandum did not affect the status of the FinCEN Memorandum, and to date, the U.S. Treasury has not given any indication that it intends to rescind the FinCEN Memorandum. While the FinCEN Memorandum was originally intended to work in tandem with the Cole Memorandum, the FinCEN Memorandum appears to remain in effect as standalone guidance. Although the FinCEN Memorandum remains intact, indicating that the U.S. Treasury and FinCEN intend to continue abiding by its guidance, it is unclear whether the Biden administration will continue to follow the guidelines set forth under the FinCEN Memorandum.

 

In March 2019, the U.S. House of Representatives introduced the Secure and Fair Enforcement Banking Act (the “SAFE Banking Act”) which creates protections for financial institutions that provide banking services to businesses acting in compliance with applicable state cannabis laws. Most recently, on July 19, 2021, the America Creating Opportunities for Manufacturing, Pre-Eminence in Technology, and Economic Strength Act of 2022 (the “America COMPETES Act of 2022”) was introduced in the U.S. House of Representatives. The America COMPETES Act of 2022 includes provisions of the SAFE Banking Act and sets out financial regulations for cannabis-related businesses and revises other aspects of the financial system with regard to cannabis-related businesses. On February 4, 2022, a majority of the U.S. House of Representatives passed the America COMPETES Act of 2022; however, it is uncertain whether it will be passed by the U.S. Senate and ultimately signed into law. This marks the sixth time that the U.S. House of Representatives have advanced SAFE Banking to the U.S. Senate. There can be no assurance that state laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions. In addition, local and city ordinances may strictly limit and/or restrict the distribution of cannabis in a manner that could make it difficult or impossible to operate cannabis businesses in certain jurisdictions.

 

Hemp

 

On December 20, 2018, the U.S. Agriculture Improvement Act of 2018 (the “2018 Farm Bill”) was signed into law. Prior to its enactment, the U.S. federal government did not distinguish between cannabis and hemp and the entire plant species Cannabis sativa L. (subject to narrow exceptions applicable to specific portions of the plant) was scheduled as a controlled substance under the CSA. Therefore, the cultivation of hemp for any purpose in the United States without a Schedule I registration with the U.S. Drug Enforcement Agency (“DEA”) was federally illegal, unless exempted by Section 7606 of the Agricultural Act of 2014 (the “2014 Farm Bill”). The 2018 Farm Bill removed hemp (which is defined as “the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis”) and its derivatives, extracts and cannabinoids, including CBD derived from hemp, from the definition of marijuana in the CSA, thereby removing hemp and its derivatives from DEA purview as a controlled substance. The 2018 Farm Bill also amends the Agricultural Marketing Act of 1946 to allow for the commercial production of hemp in the United States under the purview of the United States Department of Agriculture (the “USDA”) in coordination with state departments of agriculture that elect to have primary regulatory authority over hemp production in their respective jurisdictions. Pursuant to the 2018 Farm Bill, states, U.S. territories and tribal governments may adopt their own regulatory plans for hemp production even if more restrictive than federal regulations so long as they meet minimum federal standards and are approved by the USDA. Hemp production in states and tribal territories that do not choose to submit their own plans and that do not prohibit hemp production will be governed by USDA regulation.

 

On October 31, 2019, the USDA issued an interim final rule governing the domestic production of hemp under the 2018 Farm Bill, establishing the U.S. Domestic Hemp Production Program (the “USDA IFR”). The USDA IFR outlines the requirements for the USDA to approve plans submitted by states and tribal governments for the domestic production of hemp. It also establishes a federal plan for hemp producers in states or territories of Native American tribes that do not have USDA-approved hemp production plans. Pursuant to the USDA IFR, the USDA reviews hemp production plans submitted by state and tribal governments that wish to obtain or retain primary regulatory authority over hemp production in their respective jurisdictions. Once the USDA formally receives a plan from a state or tribal government, the agency has 60 days to review and approve or reject the plan.

 

13  
 
 

Although the USDA IFR provides the framework for the USDA, state departments of agriculture and tribal governments to begin the implementation of commercial hemp production programs pursuant to the 2018 Farm Bill, the 2014 Farm Bill was scheduled to remain in effect for one year after the effective date of the USDA IFR. On January 15, 2021, the USDA issued a final rule on hemp production which incorporates modifications established under the USDA IFR published in October 2019. The rule became effective on March 22, 2021 and outlines, among other things, the licensing requirements, recordkeeping requirements, procedures for testing THC concentrations and, procedures for disposing of non-compliant plants.

 

The application of the hemp provisions of the 2014 Farm Bill was initially set to expire on October 31, 2020, at which time state programs would be required to comply with the 2018 Farm Bill regulations. However, U.S. Senators and state agricultural departments requested an extension of the application of the 2014 Farm Bill and a delay of the implementation of the 2018 Farm Bill due to delays caused by COVID-19. Although, as a result of the extension, the 2014 Farm Bill was set to expire on December 31, 2021, it was extended until January 1, 2022, by the Continuing Appropriations Act of 2021. As of January 1, 2022, there have been no further extensions and all states must either have a USDA-approved hemp product plan, or grant regulatory oversight over hemp cultivation to the USDA.

 

Under the 2018 Farm Bill, states and tribal governments have authority to adopt regulatory regimes that are more restrictive than federal mandates or prohibit hemp production altogether. Accordingly, variance in hemp regulation across jurisdictions is likely to persist. Compliance with state hemp law, if any, is required under the 2018 Farm Bill.

As a result of the 2018 Farm Bill, federal law now provides that CBD derived from hemp is not a controlled substance under the CSA; however, CBD derived from hemp could still be considered a controlled substance under applicable state law. States take varying approaches to regulating the production and sale of hemp and hemp-derived CBD. While some states explicitly authorize and regulate the production and sale of CBD or otherwise provide legal protection for authorized individuals and businesses to engage in commercial hemp activities, other states maintain outdated drug laws that do not distinguish hemp or hemp-derived CBD from marijuana (or “cannabis” as used herein), resulting in hemp being classified as a controlled substance under certain state laws. In these states, the sale of CBD, notwithstanding its origin, is either restricted to state medical or adult-use cannabis program licensees or remains unlawful. Additionally, a number of states prohibit the sale of consumable CBD products based on the position of the FDA set forth in the Federal Food, Drug and Cosmetic Act (the “FFDCA”) that it is unlawful to introduce food containing added CBD or THC into interstate commerce, or to market CBD or THC products as or in dietary supplements regardless of whether the substances are hemp-derived.

 

The 2018 Farm Bill preserves the authority and jurisdiction of the FDA under the FFDCA to regulate the manufacture, marketing and sale of food, drugs, dietary supplements and cosmetics, including products that contain hemp extracts and derivatives such as CBD. As a producer and marketer of hemp-derived products, we are required to comply with FDA regulations applicable to the manufacturing and marketing of such products, including with respect to dietary supplements, food and cosmetics. To date, the FDA has not deemed CBD or other cannabinoids permissible for use in dietary supplements, as dietary ingredients, or as safe for use in food. The FDA has consistently taken the position that CBD is prohibited from being marketed as a dietary supplement or added to food because substantial clinical trials studying CBD as a new drug must be made public prior to the marketing of any food or dietary supplements containing CBD.

 

The FDA has issued warning letters to companies unlawfully marketing CBD products. In many of these cases, the manufacturer made unsubstantiated claims that products containing CBD are able to treat serious medical conditions, including cancer, Alzheimer’s disease, opioid withdrawal and anxiety, among others, without obtaining drug approvals. Some of these letters were co-signed with the U.S. Federal Trade Commission and cited the companies for making claims about the efficacy of CBD that were not substantiated by scientific evidence.

 

The FDA has stated that it recognizes the potential opportunities and significant interest in drugs and consumer products containing CBD, is committed to evaluating the agency’s regulatory policies related to CBD and has established a high-level internal working group to explore potential pathways for various types of CBD products to be lawfully marketed. The FDA has authority to issue regulation that would allow these naturally-occurring hemp compounds to be added to food or dietary supplements. In May 2019, the FDA held a public hearing to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling and sale of products containing cannabis or cannabis-derived compounds.

 

14  
 
 

Notwithstanding the foregoing, other than Epidiolex (cannabidiol), a cannabis-derived product, and three synthetic cannabis-related drug products (Marinol (dronabinol), Syndros (dronabinol) and Cesamet (nabilone)), the FDA has not approved a marketing application for cannabis for the treatment of any disease or condition and has not approved any cannabis, cannabis-derived or CBD products. See Risk Factors—Our products are not approved by the FDA or any other federal governmental authority; and There is uncertainty surrounding the regulatory pathway for CBD.

 

In connection with the Further Consolidated Appropriations Act, 2020, the House Committee on Appropriations issued an explanatory statement agreeing to appropriate $2.0 million in funding to the FDA for research, policy evaluation, market surveillance and issuance of an enforcement discretion policy for products under the FDA’s jurisdiction that contain CBD. The legislation required the FDA to provide a report within 60 days regarding its progress in obtaining and analyzing data to help determine a policy of enforcement discretion and the process through which CBD will be evaluated for use in products. On March 5, 2020, the FDA issued a report on its progress and committed to expanding its educational efforts regarding CBD products, encouraging, facilitating and initiating more research on CBD, continuing to monitor the CBD marketplace and take appropriate action against unlawful CBD products that pose a risk of harm to the public and developing a risk-based enforcement policy aimed at protecting the public and providing more regulatory clarity regarding the FDA’s CBD enforcement priorities. The FDA was also required to conduct a sampling study of the current CBD marketplace to determine the extent to which products containing CBD are mislabeled or adulterated within 180 days of the enactment of the Further Consolidated Appropriations Act, 2020.

 

On July 9, 2020, the FDA issued its sampling study to the U.S. House Committee on Appropriations and the U.S. Senate Committee on Appropriations detailing the sampling conducted in recent years on CBD products. While the minority of CBD products previously tested by the FDA contained CBD concentrations consistent with their labeling, the report states that a majority of products tested for potentially harmful elements “did not raise significant public health concerns.” The report further provides that the FDA will undertake a more extensive sampling effort expected to cover a representative sample of currently marketed CBD products, including tinctures, oils, extracts, capsules, powders, gummies, water and other beverages, conventional foods, cosmetics, lubricants, tampons, suppositories, vape cartridges and products sold for consumption by pets. Products will be evaluated for cannabinoid content as well as potentially harmful elements.

 

The rules, regulations and enforcement in this area continue to evolve and develop. On August 20, 2020, the DEA issued an interim final rule conforming its regulations to the 2018 Farm Bill (the “DEA IFR”), which went into effect on August 21, 2020. Notably, the DEA IFR creates uncertainty with respect to the federal legal status of any hemp derivative, extract, or product that exceeds a delta-9 tetrahydrocannabinol concentration of 0.3 percent during processing, which, pursuant to the DEA IFR, renders it a federal Schedule I substance under the CSA even if the hemp plant from which any such material is sourced does not exceed the 0.3 percent threshold.

 

On September 4, 2020, the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020 was initially introduced in the U.S. House of Representatives and was reintroduced in the U.S. House of Representatives on February 4, 2021. The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020 permits the inclusion of hemp and CBD derived from hemp as ingredients in dietary supplements that otherwise comply with the applicable requirements for dietary supplements set forth in the FFDCA and the Fair Packaging and Labeling Act. The bill does not address the inclusion of hemp or CBD derived from hemp as ingredients in food products, and it is unclear whether it will ultimately be passed and signed into law.

 

On January 8, 2021, the FDA issued a report stating that more real-world data on CBD use and safety, alongside data from other types of studies, is needed to fill in the current gaps in the FDA’s understanding of the safety profile of CBD and many other cannabis-derived compounds, including potential safety risks for people and animals. Until these gaps are filled and the FDA formally adopts regulations authorizing the production and sale of CBD products as food and/or dietary supplements, there is a risk that the FDA could take enforcement action against us. Failure to comply with FDA requirements may result in, among other things, warning letters, injunctions, product withdrawals, recalls, seizures, fines and criminal prosecutions. We continue to closely monitor FDA developments with respect to CBD and our compliance with applicable United States laws relating to hemp, including the FDA’s regulations of CBD and evaluate and implement appropriate compliance measures on an ongoing basis.

 

On February 8, 2022, the Hemp Advancement Act of 2022 was introduced in the U.S. House of Representatives. The Hemp Advancement Act of 2022 would raise the permitted THC threshold for hemp and in-process hemp extract, remove the requirement that hemp testing occur at DEA-registered facilities, and allow people with drug-related felony convictions to receive a hemp license.

 

15  
 
 

Application of Cannabis Regulations in the United States

 

Violations of U.S. federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions, or settlements arising from either civil or criminal proceedings brought by either the U.S. federal government or private citizens, including, but not limited to, disgorgement of profits, seizure of property or products, cessation of business activities, or divestiture. Our cannabis business activities and the cannabis business activities of our subsidiaries, while believed to be compliant with applicable U.S. state and local laws, currently are illegal under U.S. federal law.

 

Cannabis Regulations in Brazil

 

Brazilian law currently prohibits cannabis cultivation, processing, and sales. This restriction applies to both marijuana and industrial hemp. There is no distinction between hemp and marijuana. As a result, there is no specific legislation on industrial hemp. However, on August 18, 2020, draft legislation was introduced that would allow Brazilian farmers to grow cannabis for medical and industrial purposes on domestic soil for the first time has been submitted to the country’s lower house of Congress. The bill was delivered to the House of Deputies speaker by lawmakers Paulo Teixeira and Luciano Ducci, co-sponsors of the bill who sit on the chamber’s special commission for the regulation of medicinal cannabis. Action is pending on this legislation.

 

Cannabis Regulations in Uruguay

 

Cannabis is legal in Uruguay, and is one of the most widely used drugs in the nation. President Jose Mujica signed legislation to legalize recreational cannabis in December 2013, making Uruguay the first country in the modern era to legalize cannabis. Uruguay has an established market that the Company intends to enter and compete in.

 

Cannabis regulations in Canada

We do not, directly or indirectly, engage in the cultivation, processing, or dispensing of cannabis or any other cannabis-related activity in Canada. As such, to our knowledge, our Canadian corporate operations are not subject to any cannabis regulations in Canada.

 

Sales and Marketing

 

We market and sell our services and products throughout the United States consistent with the Farm Bill, as well as in Canada. We intend to expand our offerings as additional countries and jurisdictions who adopt state-regulated or government programs like the Farm Bill. We market and sell our hempSMART products directly through our web site, and through our affiliate marketing program, where qualified sales affiliates use a secure multi-level-marketing sales software program that facilitates order placement over the internet via a web site, and accounts for affiliate orders and sales; calculates referral benefits apportionable to specific sales associates and calculates and accounts for loyalty and rewards benefits for returning customers. The Company plans on focusing its sales and marketing through direct sales on its website and intends to wind down and terminate its affiliate marketing and sales program during fiscal 2021.

 

On March 21, 2019, our wholly owned subsidiary, hempSMART, Ltd., a corporation organized in the United Kingdom, officially launched the sales efforts for the Company’s industrial hemp CBD formulated hempSMART™ products in the United Kingdom. As of the date of this filing, our sales efforts in the UK are accomplished through our affiliate marketing program.

 

On October 1, 2020, we entered into two Joint Venture Agreements with Marco Guerrero, a director of the Company, dated September 30, 2020, to form joint venture operations in Brazil and in Uruguay to produce, manufacture, market and sell the Company’s hempSMART™ products in Latin America, and will also work to develop and sell hempSMART™ products globally. The Joint Venture Agreements contain equal terms for the formation of joint venture entities in Uruguay and Brazil. The Brazilian joint venture will be headquartered in São Paulo, Brazil, and will be named HempSmart Produtos Naturais Ltda. (“HempSmart Brazil”). The Uruguayan joint venture will be headquartered in Montevideo, Uruguay and will be named Hempsmart Uruguay S.A.S. (“HempSmart Uruguay”). Both are in the development stage.

 

Research and Development

 

Our research and development activity for the fiscal year ended December 31, 2021 was primarily focused on formulations of our various hempSMART products. Our research and development costs were $9,527. We may conduct additional research and development as the Company expands its hempSMART line of products.

 

Significant Customers

 

Sales of our hempSMART products have not resulted in reportable significant customers.

 

Intellectual Property

 

On February 12, 2019, the U. S. Patent Office issued patent number 10,201,553 for the Company’s hempSMART Brain product. On October 3, 2016, H Smart, Inc. filed a trademark application with the U.S. Patent and Trademark Office for the tradename hempSMART™, Application No. 87/531,833. The trademark has not yet been registered, and the application is pending.

 

Employees

 

As of December 31, 2021, we had 7 full-time employees.

 

16  
 
 

 

ITEM 1A. RISK FACTORS

General risk relating to COVID-19 pandemic

The novel coronavirus (COVID-19) pandemic may have an expected effect on our business, financial condition and results of operations.

In March 2020, the World Health Organization declared COVID-19 a global pandemic, and governmental authorities around the world have implemented measures to reduce the spread of COVID-19. These measures have adversely affected workforces, customers, supply chains, consumer sentiment, economies, and financial markets, and, along with decreased consumer spending, have led to an economic downturn across many global economies.

The COVID-19 pandemic has rapidly escalated in the United States, creating significant uncertainty and economic disruption, and leading to record levels of unemployment nationally. Numerous state and local jurisdictions have imposed, and others in the future may impose as variants of the virus proliferate, shelter-in-place orders, quarantines, shut-downs of non-essential businesses, and similar government orders and restrictions on their residents to control the spread of COVID-19. Such orders or restrictions have resulted in temporary facility closures, work stoppages, slowdowns and travel restrictions, among other effects, thereby adversely impacting our operations. In addition, we expect to be impacted by a downturn in the United States economy, which could have an adverse impact on discretionary consumer spending and may have a significant impact on our business operations and/or our ability to generate revenues and profits.

In response to the COVID-19 disruptions, we have implemented a number of measures designed to protect the health and safety of our staff and contractors. These measures include restrictions on non-essential business travel, the institution of work-from-home policies wherever feasible and the implementation of strategies for workplace safety at our facilities that remain open. We are following the guidance from public health officials and government agencies, including implementation of enhanced cleaning measures, social distancing guidelines and wearing of masks.

The extent to which COVID-19 ultimately impacts our business, financial condition and results of operations will depend on future developments, which are highly uncertain and unpredictable, including new information which may emerge concerning the severity and duration of the COVID-19 outbreak and the effectiveness of actions taken to contain the COVID-19 outbreak or treat its impact, among others. Additionally, while the extent to which COVID-19 ultimately impacts our operations will depend on a number of factors, many of which will be outside of our control. The COVID-19 outbreak is evolving and new information emerges daily; accordingly, the ultimate consequences of the COVID-19 outbreak cannot be predicted with certainty. In addition to the COVID-19 disruptions possibility adversely impacting our business and financial results, they may also have the effect of heightening many of the other risks described in “Risk Factors,” including risks relating to changes due to our limited operating history; our ability to generate sufficient revenue, to generate positive cash flow; our relationships with third parties, and many other factors. We will endeavor to minimize these impacts, but there can be no assurance relative to the potential impacts that may be incurred.

17  
 
 

Risks Related to Our Business

Our business and financial results may be materially adversely affected by the current COVID-19 pandemic outbreak.

 

The pandemic of a novel coronavirus (COVID-19) has resulted in a widespread health crisis that has adversely affected the economies and financial markets worldwide. Government efforts to contain the spread of the coronavirus through lockdowns of cities, business closures, restrictions on travel and emergency quarantines, among others, and responses by businesses and individuals to reduce the risk of exposure to infection, including reduced travel, cancellation of meetings and events, and implementation of work-at- home policies, among others, have caused significant disruptions to the global economy and normal business operations across a growing list of sectors and countries. 

Our operating results substantially depend on revenues derived from sales of hemp and cannabis-derived products on a wholesale and retail basis. As the COVID-19 spread continues, the measures implemented to curb the spread of the virus have resulted in supply chain disruptions, insufficient work force and suspended manufacturing and construction works for the cannabis industry. One or more of our customers, partners, service providers or suppliers may experience financial distress, delayed or defaults on payment, file for bankruptcy protection, sharp diminishing of business, or suffer disruptions in their business due to the outbreak. These preventative measures have also impacted our daily operations. The efforts enacted to control COVID-19 have placed heavy pressure on our marketing and sales activities. We continue to assess the related risks and impacts COVID-19 pandemic may have on our business and our financial performance. In light of the rapidly changing situation across different countries and regions, it remains difficult to estimate the duration and magnitude of COVID-19 impact. Until such time as the COVID-19 pandemic is contained or eradicated and global business return to more customary levels, our business and financial results may be materially adversely affected.

The Farm Bill recently passed, and undeveloped shared state-federal regulations over hemp cultivation and production may impact our business.

The Farm Bill was signed into law on December 20, 2018. Under Section 10113 of the Farm Bill, state departments of agriculture must consult with the state’s governor and chief law enforcement officer to devise a plan that must be submitted to the Secretary of USDA. A state’s plan to license and regulate hemp can only commence once the Secretary of USDA approves that state’s plan. In states opting not to devise a hemp regulatory program, USDA will need to construct a regulatory program under which hemp cultivators in those states must apply for licenses and comply with a federally-run program. The details and scopes of each state’s plans are not fully known at this time and may contain varying regulations that may impact our business. Even if a state creates a plan in conjunction with its governor and chief law enforcement officer, the Secretary of the USDA must approve it. There can be no guarantee that any state plan will be approved. Review times may be extensive. There may be amendments and the ultimate plans, if approved by states and the USDA, may materially limit our business depending upon the scope of the regulations.

Laws and regulations affecting our industry to be developed under the Farm Bill are in development.

As a result of the Farm Bill’s recent passage, laws and regulations affecting the hemp industry will evolve which could detrimentally affect our operations. Local, state and federal hemp laws and regulations may be broad in scope and subject to changing interpretations. These changes may require us to incur substantial costs associated with legal and compliance fees and ultimately require us to alter our business plan. Furthermore, violations of these laws, or alleged violations, could disrupt our business and result in a material adverse effect on our operations. In addition, we cannot predict the nature of any future laws, regulations, interpretations or applications, and it is possible that regulations may be enacted in the future that will be directly applicable to our business.

Psychoactive Cannabis and derivatives are illegal under the CSA.

Psychoactive Cannabis and derivatives are Schedule 1 controlled substances and are illegal under the CSA. Even in states that have legalized the use of Psychoactive Cannabis, its sale and use remain violations of federal law. The illegality of Psychoactive Cannabis under the CSA preempts state laws that legalize its use. Therefore, strict enforcement of the CSA regarding Psychoactive Cannabis and derivatives would likely result in Natural Plant Extracts of California, Inc.’s inability to proceed with its business plans involving operating a psychoactive cannabis delivery service in California. This event would cause us to suffer losses related to our 5% interest in Natural Plant Extracts of California, Inc.

18  
 
 

Our CEO, Jesus Quintero, will hold in excess of 50% of the voting power of our capital stock for the foreseeable future. If the voting power of our capital stock continues to be highly concentrated, it may prevent you and other minority stockholders from influencing significant corporate decisions and may result in conflicts of interest.

 

Jesus Quintero, our CEO, will continue to control in excess of 50% of the voting power of our outstanding capital stock for at least as long as he continues to hold the Series A and B Preferred Stock. As a result, Mr. Quintero will have majority voting power over all matters requiring stockholder votes, including: the election of directors; mergers, consolidations, and acquisitions; the sale of all or substantially all of our assets and other decisions affecting our capital structure; amendments to our certificate of incorporation or our bylaws; and our winding up and dissolution.

 

This concentration of voting power may delay, deter or prevent acts that would be favored by our other stockholders. The interests of Mr. Quintero may not always coincide with our interests or the interests of our other stockholders. This concentration of voting power may also have the effect of delaying, preventing or deterring a change in control of us. Also, Mr. Quintero may seek to cause us to take courses of action that, in his judgment, could enhance his investment in us, but which might involve risks to our other stockholders or adversely affect us or our other stockholders, including investors in this offering. As a result, the market price of our common stock could decline, or our other stockholders might not receive a premium over the then-current market price of our common stock upon a change in control. In addition, this concentration of voting power may adversely affect the trading price of our common stock because investors may perceive disadvantages in owning shares in a company with significant stockholders.

 

We are a holding company, and our principal assets are held by subsidiaries, and accordingly we are dependent upon distributions from such operating subsidiaries to pay taxes and other expenses.

 

We are a holding company, and our principal assets are held by subsidiaries. Accordingly, we are dependent upon distributions from our operating subsidiaries to pay taxes and other expenses. If our operating subsidiaries do not generate sufficient revenues such that they can provide distributions to us, we may be unable to pay our expenses which would have a materially adverse effect on our business operations and our Company as a whole.

 

We may fail to successfully execute our business plan.

 

Our shareholders may lose their entire investment if we fail to execute our business plan. Our prospects must be considered in light of the following risks and uncertainties, including but not limited to, competition, the erosion of ongoing revenue streams, the ability to retain experienced personnel and general economic conditions. We cannot guarantee that we will be successful in executing our business plan. If we fail to successfully execute our business plan, we may be forced to cease operations, in which case our shareholders may lose their entire investment.

 

We may have difficulties integrating acquisitions or identifying new acquisitions.

 

A major part of our strategy is to grow through acquisition. However, we may be unable to identify and consummate additional acquisitions or may be unable to successfully integrate and manage the product lines or businesses that we have recently acquired or may acquire in the future. In addition, we may be unable to achieve a substantial portion of any anticipated cost savings from acquisitions or other anticipated benefits in the timeframe we anticipate, or at all. Moreover, any acquired product lines or businesses may require a greater than anticipated amount of trade, promotional and capital spending. Acquisitions involve numerous risks, including difficulties in the assimilation of the operations, technologies, services and products of the acquired companies, personnel turnover and the diversion of management’s attention from other business concerns. Any inability by us to integrate and manage any product lines or businesses that we have recently acquired or may acquire in the future in a timely and efficient manner, any inability to achieve a substantial portion of any anticipated cost savings or other anticipated benefits from these acquisitions in the time frame we anticipate or any unanticipated required increases in trade, promotional or capital spending could adversely affect our business, consolidated financial condition, results of operations or liquidity. Moreover, future acquisitions by us could result in our incurring substantial additional indebtedness, being exposed to contingent liabilities or incurring the impairment of goodwill and other intangible assets, all of which could adversely affect our financial condition, results of operations and liquidity.

 

19  
 
 

Risk of government action.

While we will use our best efforts to comply with all laws and regulations, there is a possibility that governmental action to enforce any alleged violations may result in legal fees and damage awards that would adversely affect us.

We anticipate our operating expenses will increase, and we may never achieve profitability.

We launched our first hempSMART™ product, hempSMART Brain™, in November 2016. Since then, we have introduced a number of other consumer products, including hempSMART Pain™, hempSMART™ Full Spectrum Pet Drops™, and hempSMART™ Full Spectrum Drops™. As we continue to produce other hempSMART™ products, we anticipate increases in our operating expenses, without realizing significant revenues from operations. Within the next 12 months, these increases in expenses will be attributed to the cost of (i) general and administrative, (ii) new research and development, (iii) advertising and website development, (iv) legal and accounting fees at various stages of operation, (v) joint venture activities, (vi) creating and maintaining distribution and supply chain channels.

As a result of some or all of these factors in combination, we will incur significant financial losses in the foreseeable future. There is no history upon which to base any assumption as to the likelihood that our Company will prove successful. We cannot provide investors with any assurance that our business will attract customers and investors. If we are unable to address these risks, there is a high probability that our business will fail.

Because our business is dependent upon continued market acceptance by consumers, any negative trends will adversely affect our business operations.

We are substantially dependent on continued market acceptance and proliferation of consumers of hemp and hemp-derived CBD. We believe that as hemp and hemp-derived CBD becomes more accepted as a result of the passage of the Farm Bill, the stigma associated with hemp and CBD will diminish and as a result consumer demand will continue to grow. While we believe that the market and opportunity in the hemp space continues to grow, we cannot predict the future growth rate and size of the market. Any negative outlook on the hemp industry will adversely affect our business operations.

The possible FDA Regulation of hemp and industrial hemp derived CBD, and the possible registration of facilities where hemp is grown and CBD products are produced, if implemented, could negatively affect the hemp industry generally, which could directly affect our financial condition.

The Farm Bill established that hemp containing less the 0.3% THC was no longer a Schedule 1 drug under the CSA. Previously, the U.S. Food and Drug Administration (“FDA”) did not approve hemp or CBD derived from hemp as a safe and effective drug for any indication. The FDA considered hemp and hemp-derived CBD as illegal Schedule 1 drugs. Further, the FDA has concluded that products containing hemp or CBD derived from hemp are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the U.S. Food, Drug & Cosmetic Act, respectively. However, as a result of the passage of the Farm Bill, at some indeterminate future time, the FDA may choose to change its position concerning products containing hemp, or CBD derived from hemp, and may choose to enact regulations that are applicable to such products, including, but not limited to: the growth, cultivation, harvesting and processing of hemp; regulations covering the physical facilities where hemp is grown and processed; and possible testing to determine efficacy and safety of hemp derived CBD. In this hypothetical event, our hemp-based hempSMART™ products containing CBD may be subject to regulation. In the hypothetical event that some or all of these regulations are imposed, we do not know what the impact would be on the hemp industry in general, and what costs, requirements and possible prohibitions may be enforced. If we are unable to comply with the conditions and possible costs of possible regulations and/or registration as may be prescribed by the FDA, we may be unable to continue to operate our business.

20  
 
 

Laws governing our access to banking services remain uncertain and are in a state of flux.

On February 14, 2014, the U.S. government issued rules allowing banks to legally provide financial services to state-licensed cannabis businesses. A memorandum issued by the Justice Department to federal prosecutors re-iterated guidance previously given, this time to the financial industry, that banks can do business with legal cannabis businesses and “may not” be prosecuted. We believe this applies to hemp and to Psychoactive Cannabis. The Treasury Department’s Financial Crimes Enforcement Network (FinCEN) issued guidelines to banks that “it is possible to provide financial services” to state-licensed cannabis (and hemp) businesses and still be in compliance with federal anti-money laundering laws. These provisions created barriers to our banking operations. With the passage of the Farm Bill, we expect that the banking industry will be more open to doing business with compliant hemp businesses. Currently, the U.S. Congress is considering the Secure and Fair Enforcement Banking Act sponsored by Reps. Ed Perlmutter (D-CO) Denny Heck (D-WA), Steve Stivers (R-OH) and Warren Davidson (R-OH) filed in March, 2019 designed to protect banks that service the marijuana industry from being penalized by federal regulators. The act currently has 138 cosponsors—more than a quarter of the House. However, this may take time and may not result in a more open banking climate. We expect that banks will be more open to serving cannabis and hemp businesses, but there is no guarantee – even with the passage of the Farm Bill.

Banking regulations in our business are costly and time consuming.

In assessing the prospective risk of providing services to a hemp-related business, a financial institutions may conduct customer due diligence that includes: (i) verifying with the appropriate state authorities whether the business is duly licensed and registered; (ii) reviewing the license application (and related documentation) submitted by the business for obtaining a state license to operate its cannabis-related business; (iii) requesting from state licensing and enforcement authorities available information about the business and related parties; (iv) developing an understanding of the normal and expected activity for the business, including the types of products to be sold; (v) ongoing monitoring of publicly available sources for adverse information about the business and related parties; (vi) ongoing monitoring for suspicious activity, including for any of the red flags described in this guidance; and (vii) refreshing information obtained as part of customer due diligence on a periodic basis and commensurate with the risk. With respect to information regarding state licensure obtained in connection with such customer due diligence, a financial institution may reasonably rely on the accuracy of information provided by state licensing authorities, where states make such information available. These regulatory reviews may be time consuming and costly.

Due to our involvement in the hemp industry and the Psychoactive Cannabis delivery business, we may have a difficult time obtaining the various insurances that are desired to operate our business, which may expose us to additional risk and financial liability.

Insurance that is otherwise readily available, such as general liability, and directors and officer’s insurance, is more difficult for us to find, and more expensive, because we are service providers to companies in the cannabis industry. There are no guarantees that we will be able to find such insurances in the future, or that the cost will be affordable to us. If we are forced to go without such insurances, it may prevent us from entering into certain business sectors, may inhibit our growth, and may expose us to additional risk and financial liabilities.

The Company’s industry is highly competitive, and we have less capital and resources than many of our competitors which may give them and advantage in developing and marketing products similar to ours or make our products obsolete.

We are involved in a highly competitive industry where we may compete with numerous other companies who offer alternative hemp products and derivatives, who may have far greater resources, more experience, and personnel perhaps more qualified than we do. Such resources may give our competitors an advantage in developing and marketing products similar to ours or products that make our products less desirable to consumers or obsolete. There can be no assurance that we will be able to successfully compete against these other entities.

We may be unable to respond to the rapid technological change in the industry and such change may increase costs and competition that may adversely affect our business.

Rapidly changing technologies, frequent new product and service introductions and evolving industry standards characterize our market. The continued growth of the Internet and intense competition in our industry exacerbates these market characteristics. Our future success will depend on our ability to adapt to rapidly changing technologies by continually improving the performance features and reliability of our hempSMART™ products. We may experience difficulties that could delay or prevent the successful development, introduction or marketing of our hempSMART™ products. In addition, any new enhancements must meet the requirements of our current and prospective customers and must achieve significant market acceptance. We could also incur substantial costs if we need to modify our hempSMART™ products and services or infrastructures to adapt to these changes.

We also expect that new competitors may introduce products or services that are directly or indirectly competitive with us. These competitors may succeed in developing, products and services that have greater functionality or are less costly than our products and services and may be more successful in marketing such products and services. Technological changes have lowered the cost of operating communications and computer systems and purchasing software. These changes reduce our cost of selling products and providing services, but also facilitate increased competition by reducing competitors’ costs in providing similar services. This competition could increase price competition and reduce anticipated profit margins.

21  
 
 

 

Our hempSMART™ products are relatively new and our industry is rapidly evolving.

Due consideration must be given to our prospects in light of the risks, uncertainties and difficulties frequently encountered by companies in their early stage of development, particularly companies in the rapidly evolving legal cannabis and hemp industries. To be successful we must, among other things:

•       Develop, manufacture and introduce new attractive and successful consumer products in our hempSMART™ brand.

•       Attract and maintain a large customer base and develop and grow that customer base.

•       Increase awareness of our hempSMART™ brand and develop effective marketing strategies to insure consumer loyalty.

•       Establish and maintain strategic relationships with key sales, marketing, manufacturing and distribution providers.

•       Respond to competitive and technological developments.

•       Attract, retain and motivate qualified personnel.

We may be unable to fully capture the expected value from our new joint venture operations in Brazil and Uruguay.

In connection with our entry into new joint ventures in Brazil and Uruguay, we face numerous risks and uncertainties, including effectively integrating our respective personnel, management controls and business relationships into an effective and cohesive operation. Further, we are subject to additional risks and uncertainties because we may be dependent upon, and subject to, liability losses or damages relating to system controls and personnel that are not under our control. The joint venture business may be subject to unforeseeable negative market conditions, economic downturns, and legal and political considerations in Brazil and Uruguay. While cannabis and hemp are legalized in Uruguay, Brazil is only considering legalization as of the date of this filing, and legalization there is not guaranteed.

Our joint ventures in Brazil and Uruguay will rely significantly upon the activities of our joint venture partners. We will rely upon our joint venture partner’s Brazilian and Uruguayan personnel, business acumen, experience and involvement to seek economic success and the joint ventures’ compliance with applicable Brazilian and Uruguayan laws.

If we are unable to integrate and monitor our Brazilian and Uruguayan joint ventures successfully and efficiently, there is a risk that our results of operations, financial condition and cash flows may be materially and adversely affected. In addition, conflicts or disagreements between us and our joint venture partners in Brazil and Uruguay may negatively impact the benefits to be achieved by the relevant joint venture. There is no assurance that our joint ventures will be successfully integrated or yield all of the positive benefits anticipated.

Our joint venture investments in Latin America, and other joint venture investments that we make in the future, could be adversely affected by our lack of sole decision-making authority, our reliance on co-venturers’ financial condition and liquidity and disputes between us and our co-venturers.

In addition to our new joint venture projects in Brazil and Uruguay, which are in development stage, will require financial investment on our part, and have not yet generated revenue for the Company, we may co-invest in other joint ventures in the future with third parties through partnerships or other joint ventures, acquiring non-controlling interests in or sharing responsibility for any such ventures. In this event, we would not be in a position to exercise sole decision-making authority regarding the joint venture and, in certain cases, may have little or no decision-making authority. Investments through partnerships or other joint ventures may, under certain circumstances, involve risks not present were a third party not involved, including the possibility that partners or co-venturers might become bankrupt, fail to fund their share of required capital contributions, make dubious business decisions or block or delay necessary decisions. Partners or co-venturers may have economic or other business interests or goals which are inconsistent with our business interests or goals, and may be in a position to take actions contrary to our policies or objectives. Such investments may also have the potential risk of impasses on decisions, such as a sale, because neither we nor the partner or co-venturer would have full control over the partnership or joint venture. Disputes between us and partners or co-venturers may result in litigation or arbitration that would increase our expenses and prevent our executive officers, senior management and/or directors from focusing their time and effort on our business. Consequently, action by, or disputes with, partners or co-venturers might result in subjecting properties owned by the partnership or joint venture to additional risk. In addition, we may in certain circumstances be liable for the actions of our third-party partners or co-venturers.

 

22  
 
 

We cannot guarantee that we will succeed in achieving our goals, and our failure to do so would have a material adverse effect on our business, prospects, financial condition and operating results.

Some of our hempSMART™ products are new and are only in the developmental stages of commercialization. We are not certain that these products will function as anticipated or be desirable to their intended markets. Also, some of our products may have limited functionalities, which may limit their appeal to consumers and put us at a competitive disadvantage. If our current or future hempSMART™ products fail to function properly or if we do not achieve or sustain market acceptance, we could lose customers or could be subject to claims which could have a material adverse effect on our business, financial condition and operating results.

As is typical in a new and rapidly evolving industry, demand and market acceptance for recently introduced products and services are subject to a high level of uncertainty and risk. Because the market for our Company is evolving, it is difficult to predict with any certainty the ultimate size of this market and its growth rate, if any. We cannot guarantee that a market for our products will develop or that demand for our products will emerge or be sustainable. If the market fails to develop, develops more slowly than expected or becomes saturated with competitors, our business, financial condition and operating results would be materially adversely affected.

The Company’s failure to continue to attract, train, or retain highly qualified personnel could harm the Company’s business.

The Company’s success also depends on the Company’s ability to attract, train, and retain qualified personnel, specifically those with management and product development skills. In particular, the Company must hire additional skilled personnel to further the Company’s research and development efforts. Competition for such personnel is intense. If the Company does not succeed in attracting new personnel or retaining and motivating the Company’s current personnel, the Company’s business could be harmed.

The loss of key management personnel could adversely affect our business.

We depend on the continued services of our executive officers and senior management team as they work closely with independent associate leaders and are responsible for our day-to-day operations. Our success depends in part on our ability to retain our executive officers, to compensate our executive officers at attractive levels, and to continue to attract additional qualified individuals to our management team. Although we have entered into employment agreements with our senior management team, and do not believe that any of them are planning to leave or retire in the near term, we cannot assure that our senior managers will remain with us. The loss or limitation of the services of any of our executive officers or members of our senior management team, or the inability to attract additional qualified management personnel, could have a material adverse effect on our business, financial condition, results of operations, or independent associate relations.

 

23  
 
 

There could be unidentified risks involved with an investment in our securities.

The foregoing risk factors are not a complete list or explanation of the risks involved with an investment in the securities. Additional risks will likely be experienced that are not presently foreseen by the Company. Prospective investors must not construe this the information provided herein as constituting investment, legal, tax or other professional advice. Before making any decision to invest in our securities, you should read this entire prospectus and consult with your own investment, legal, tax and other professional advisors. An investment in our securities is suitable only for investors who can assume the financial risks of an investment in the Company for an indefinite period of time and who can afford to lose their entire investment. The Company makes no representations or warranties of any kind with respect to the likelihood of the success or the business of the Company, the value of our securities, any financial returns that may be generated or any tax benefits or consequences that may result from an investment in the Company.

Risks Related to the Company

Uncertainty of profitability

Our business strategy may result in increased volatility of revenues and earnings. As we will only develop a limited number of products at a time, our overall success will depend on a limited number of products, which may cause variability and unsteady profits and losses depending on the products and/or services offered and their market acceptance.

Our revenues and our profitability may be adversely affected by economic conditions and changes in the market for our products. Our business is also subject to general economic risks that could adversely impact the results of operations and financial condition.

Because of the anticipated nature of the products that we offer and attempt to develop, it is difficult to accurately forecast revenues and operating results and these items could fluctuate in the future due to a number of factors. These factors may include, among other things, the following:

•       Our ability to raise sufficient capital to take advantage of opportunities and generate sufficient revenues to cover expenses.

•       Our ability to source strong opportunities with sufficient risk adjusted returns.

•       Our ability to manage our capital and liquidity requirements based on changing market conditions generally and changes in the developing legal medical marijuana and recreational marijuana industries.

•       The acceptance of the terms and conditions of our multi-level sales agreements.

•       The amount and timing of operating and other costs and expenses.

•       The nature and extent of competition from other companies that may reduce market share and create pressure on pricing and investment return expectations.

•       Adverse changes in the national and regional economies in which we will participate, including, but not limited to, changes in our performance, capital availability, and market demand.

•       Adverse changes in the projects in which we plan to invest which result from factors beyond our control, including, but not limited to, a change in circumstances, capacity and economic impacts.

•       Adverse developments in the efforts to legalize cannabis or increased federal enforcement.

•       Changes in laws, regulations, accounting, taxation, and other requirements affecting our operations and business.

•       Our operating results may fluctuate from year to year due to the factors listed above and others not listed. At times, these fluctuations may be significant.

 

24  
 
 

 

Management of growth will be necessary for us to be competitive.

Successful expansion of our business will depend on our ability to effectively attract and manage staff, strategic business relationships, and shareholders. Specifically, we will need to hire skilled management and technical personnel as well as manage partnerships to navigate shifts in the general economic environment. Expansion has the potential to place significant strains on financial, management, and operational resources, yet failure to expand will inhibit our profitability goals.

We are operating in a highly competitive market.

The markets for businesses in the hemp industry is competitive and evolving. In particular, we face strong competition from larger companies that may be in the process of offering similar products and services to ours. Many of our current and potential competitors have longer operating histories, significantly greater financial, marketing and other resources and larger client bases than we have (or may be expected to have).

Given the rapid changes affecting the global, national, and regional economies generally and the cannabis and hemp industries, in particular, we may not be able to create and maintain a competitive advantage in the marketplace. Our success will depend on our ability to keep pace with any changes in its markets, especially with legal and regulatory changes. Our success will depend on our ability to respond to, among other things, changes in the economy, market conditions, and competitive pressures. Any failure by us to anticipate or respond adequately to such changes could have a material adverse effect on our financial condition, operating results, liquidity, cash flow and our operational performance.

It is unknown whether the passage of the Farm Bill will provide us trademark protection for our hempSMART™ brand and products.

We have applied for a trademark for our hempSMART™ brand name. Before passage of the Farm Bill, we were uncertain that we could obtain patent or trademark protection for our products Because hemp derived CBD was considered an illegal Schedule 1 drug under the CSA at the time. With the passage of the Farm Bill, we may be able to overcome these uncertainties, since hemp containing less than 0.3% THC is no longer a Schedule 1 drug under the CSA. However, we cannot guarantee more favorable treatment and the failure to obtain trademark protection may materially impact our brand establishment, sales and good will.

If we fail to protect our intellectual property, our business could be adversely affected.

Our viability will depend, in part, on our ability to develop and maintain the proprietary aspects of our hempSMART™ products and brand to distinguish our hempSMART™ products and services from our competitors’ products and services. We rely on patents, copyrights, trademarks, trade secrets, and confidentiality provisions to establish and protect our intellectual property.

Any infringement or misappropriation of our intellectual property could damage its value and limit our ability to compete. We may have to engage in litigation to protect the rights to our intellectual property, which could result in significant litigation costs and require a significant amount of our time.

Competitors may also harm our sales by designing products that mirror the capabilities of our products or technology without infringing on our intellectual property rights. If we do not obtain sufficient protection for our intellectual property, or if we are unable to effectively enforce our intellectual property rights, our competitiveness could be impaired, which would limit our growth and future revenue.

We may also find it necessary to bring infringement or other actions against third parties to seek to protect our intellectual property rights. Litigation of this nature, even if successful, is often expensive and time-consuming to prosecute, and there can be no assurance that we will have the financial or other resources to enforce our rights or be able to enforce our rights or prevent other parties from developing similar technology or designing around our intellectual property.

25  
 
 

Our trade secrets may be difficult to protect.

Our success depends upon the skills, knowledge and experience of our scientific and technical personnel, our consultants and advisors, as well as our contractors. Because we operate in a highly competitive industry, we rely in part on trade secrets to protect our proprietary hempSMART™ products and processes. However, trade secrets are difficult to protect. We enter into confidentiality or non-disclosure agreements with our corporate partners, employees, consultants, outside scientific collaborators, developers and other advisors. These agreements generally require that the receiving party keep confidential and not disclose to third party’s confidential information developed by the receiving party or made known to the receiving party by us during the course of the receiving party’s relationship with us. These agreements also generally provide that inventions conceived by the receiving party in the course of rendering services to us will be our exclusive property, and we enter into assignment agreements to perfect our rights.

These confidentiality, inventions and assignment agreements may be breached and may not effectively assign intellectual property rights to us. Our trade secrets also could be independently discovered by competitors, in which case we would not be able to prevent the use of such trade secrets by our competitors. The enforcement of a claim alleging that a party illegally obtained and was using our trade secrets could be difficult, expensive and time consuming and the outcome would be unpredictable. The failure to obtain or maintain meaningful trade secret protection could adversely affect our competitive position.

Our business may be affected by unusual weather patterns.

The production of some of our hempSMART™ products relies on the availability and use of live hemp plant material. Growing periods can be impacted by weather patterns and these unpredictable weather patterns may impact our ability to harvest hemp. In addition, severe weather, including drought and hail, can destroy a hemp crop, which could result in our having no hemp to harvest, process and sell. If our suppliers are unable to obtain sufficient hemp from which to process CBD, our ability to meet customer demand, generate sales, and maintain operations will be impacted.

Our hempSMART™ sales in the UK may be subject to unforeseeable events and regulation that may have a material impact on our efforts to sell our hempSMART™ products in the UK.

Currently, the UK regulates wellness products containing CBD through its Medicines and Healthcare products Regulatory Agency (“MHRA”). Pursuant to the MHRA, only wellness products containing less than 0.2% THC may be sold in the UK. Our latest laboratory results from testing the THC content of our hempSMART™ products containing CBD derived from industrial hemp show that our products approach 0% THC. While we are confident that our hempSMART™ products are compliant with regulations in both the UK, these regulations may change unforeseeably, and any such changes may have a material effect on our ability to market and sell our hempSMART™ products in the UK. Additionally, we rely on affiliates in the UK for the administration of our business there. We have not to date established an effective warehousing protocol to efficiently store and deliver products there. The failure of our UK affiliates to efficiently handle the storage and distribution of our products could create a material deficiency in conducting our business there.

26  
 
 

 

Risks Related to Our Common Stock

Because we may issue additional shares of our common stock, investment in our company could be subject to substantial dilution.

Investors’ interests in our Company will be diluted and investors may suffer dilution in their net book value per share when we issue additional shares. Dilution is the difference between what investors pay for their stock and the net tangible book value per share immediately after the additional shares are sold by us. We are authorized to issue 22,000,000,000 shares of common stock, no par value per share. As of January 31, 2022 there were 7,142,889,498 shares of our common stock in the public float. Our financing activities in the past focused on convertible note financing that requires us to issue shares of common stock to satisfy principal, interest and any applicable penalties related to these convertible notes. When required under the terms and conditions of the convertible notes, we issue additional shares of common stock that have a dilutive effect on our stockholders. We anticipate that all or at least some of our future funding, if any, will be in the form of equity financing from the sale of our common stock and so any investment in our company will be diluted, with a resulting decline in the value of our common stock.

Trading in our common stock on the OTC Pink Tier Exchange has been subject to wide fluctuations.

Our common stock is currently quoted for public trading on the OTC Pink Market Tier. The trading price of our common stock has been subject to wide fluctuations. Trading prices of our common stock may fluctuate in response to a number of factors, many of which will be beyond our control, including our issuance of additional common shares at variable prices to our convertible note holders. The stock market has generally experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies with limited business operation. There can be no assurance that trading prices and price earnings ratios previously experienced by our common stock will be matched or maintained. These broad market and industry factors may adversely affect the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market price of a company’s securities, securities class-action litigation has often been instituted. Such litigation, if instituted, could result in substantial costs for us and a diversion of management’s attention and resources.

Our common stock has been delisted from OTC Markets OTCQB listing tier to OTC Markets Pink listing tier.

Our common stock traded below $0.01 per share on the OTC Markets’ QB trading tier for more than 30 consecutive calendar days, and as a result we no longer met the Standards for Continued Eligibility for OTCQB as per the OTCQB Standards, Section 2.3(2), which state that the company must “maintain proprietary priced quotations published by a Market Maker in OTC Link with a minimum closing bid price of $.01 per share on at least one of the prior thirty consecutive calendar days.”

As per Section 4.1 of the OTCQB Standards, the Company was granted a cure period of 90 calendar days, and at the Company’s petition, the OTCQB granted the Company an extension from this requirement, until October 2020. However, the Company did not meet the requirement and was down-listed from the OTCQB marketplace to the OTC Markets Pink listing tier.

27  
 
 

 

Utah law, our Certificate of Incorporation and our by-laws provides for the indemnification of our officers and directors at our expense, and correspondingly limits their liability, which may result in a major cost to us and hurt the interests of our shareholders because corporate resources may be expended for the benefit of officers and/or directors.

Our Certificate of Incorporation and By-Laws include provisions that eliminate the personal liability of our directors for monetary damages to the fullest extent possible under the laws of the State of Utah or other applicable law. These provisions eliminate the liability of our directors and our shareholders for monetary damages arising out of any violation of a director of his fiduciary duty of due care. Under Utah law, however, such provisions do not eliminate the personal liability of a director for (i) breach of the director’s duty of loyalty, (ii) acts or omissions not in good faith or involving intentional misconduct or knowing violation of law, (iii) payment of dividends or repurchases of stock other than from lawfully available funds, or (iv) any transaction from which the director derived an improper benefit. These provisions do not affect a director’s liabilities under the federal securities laws or the recovery of damages by third parties.

We do not intend to pay cash dividends on any investment in the shares of stock of our Company and any gain on an investment in our Company will need to come through an increase in our stock’s price, which may never happen.

We have never paid any cash dividends and currently do not intend to pay any cash dividends for the foreseeable future. To the extent that we require additional funding currently not provided for, our funding sources may prohibit the payment of a dividend. Because we do not currently intend to declare dividends, any gain on an investment in our company will need to come through an increase in the stock’s price. This may never happen, and investors may lose all of their investment in our company.

FINRA sales practice requirements may  also limit a stockholder’s ability to buy and sell our stock.

The Financial Industry Regulatory Authority (known as “FINRA”) has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common shares, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares.

The number of brokerage firms depositing and transacting trades for penny stock companies with a bid price of below one penny is very limited.

Currently, our common stock is traded on the OTC Markets Pink Tier with closing bid and ask prices below one penny. Many traditional brokerage firms and on-line brokerages refuse to accept for deposit and trade any penny stocks generally. For those that do, the time, effort and costs associated with depositing common stock in companies such as our with a sub-penny bid and ask are onerous, time consuming and costly. This may present material concerns and obstacles to those persons beneficially owning our common stock in certificate or book entry form, and wish to deposit same into a brokerage account.

 

Costs and expenses of being a reporting company under the 1934 Securities and Exchange Act may be burdensome and prevent us from achieving profitability.

As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and parts of the Sarbanes-Oxley Act. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting and financial compliance costs, make some activities more difficult, time-consuming and costly, and place significant strain on our personnel, systems and resources.

There could be unidentified risks involved with an investment in our securities.

The foregoing risk factors are not a complete list or explanation of the risks involved with an investment in the securities. Additional risks will likely be experienced that are not presently foreseen by the Company. Prospective investors must not construe this the information provided herein as constituting investment, legal, tax or other professional advice. Before making any decision to invest in our securities, you should read this entire prospectus and consult with your own investment, legal, tax and other professional advisors. An investment in our securities is suitable only for investors who can assume the financial risks of an investment in the Company for an indefinite period of time and who can afford to lose their entire investment. The Company makes no representations or warranties of any kind with respect to the likelihood of the success or the business of the Company, the value of our securities, any financial returns that may be generated or any tax benefits or consequences that may result from an investment in the Company.  

28  
 
 

ITEM 1B.   UNRESOLVED STAFF COMMENTS

 

Inapplicable as we are not a large accelerated filer, as defined in Rule 12b-2 of the Exchange Act, or a well-known seasoned issuer as defined in Rule 405 of the Securities Act.  

 

ITEM 2.    PROPERTIES

 

We maintain a lease for our principal office located at 633 W. 5th Street, Suite 2826, Los Angeles, California 90071.

 

ITEM 3.     LEGAL PROCEEDINGS

 

On September 20, 2018, the Company filed suit against Bougainville Ventures, Inc., BV-MCOA Management, LLC, Andy Jagpal, Richard Cindric, et al. in Okanogan County Washington Superior Court, case number 18-2- 0045324.

 

Background. On March 16, 2017, we entered into a joint venture agreement with Bougainville Ventures, Inc., a Canadian corporation. The purpose of the joint venture was for the Company and Bougainville to jointly engage in the development and promotion of products in the legalized cannabis industry in Washington State; (ii) utilize Bougainville’s high quality cannabis grow operations in the State of Washington, where it claimed to have an ownership interest in real property for use within the legalized cannabis industry; (iii) leverage Bougainville’s agreement with a I502 Tier 3 license holder to grow cannabis on the site; provide technical and management services and resources including, but not limited to: sales and marketing, agricultural procedures, operations security and monitoring, processing and delivery, branding, capital resources and financial management; and, (iv) optimize collaborative business opportunities. The Company and Bougainville agreed to operate through a Washington State Limited Liability Company, and BV-MCOA Management, LLC was organized in the State of Washington on May 16, 2017.

 

As our contribution to the joint venture, the Company committed to raise not less than $1 million dollars to fund joint venture operations based upon a funding schedule. The Company also committed to providing branding and systems for the representation of cannabis related products and derivatives comprised of management, marketing and various proprietary methodologies directly tailored to the cannabis industry. The Company and Bougainville's agreement provided that funding provided by the Company would go, in part, towards the joint venture’s ultimate purchase of the land consisting of a one-acre parcel located in Okanogan County, Washington, for joint venture operations.

 

As disclosed on Form 8-K on December 11, 2017, the Company did not comply with the funding schedule for the joint venture. On November 6, 2017, the Company and Bougainville amended the joint venture agreement to reduce the amount of the Company's commitment to $800,000 and also required the Company to issue Bougainville 15 million shares of the Company's restricted common stock. The Company completed its payments pursuant to the amended agreement on November 7, 2017, and on November 9, 2017, issued to Bougainville 15 million shares of restricted common stock. The amended agreement provided that Bougainville would deed the real property to the joint venture within thirty days of its receipt of payment.

29  
 
 

Thereafter, the Company determined that Bougainville had no ownership interest in the property in Washington State, but rather was a party to a purchase agreement for real property that was in breach for non-payment. Bougainville also did not possess an agreement with a Tier 3 I502 license holder to grow Marijuana on the property. Nonetheless, as a result of funding arranged for by the Company, Bougainville and an unrelated third party, Green Ventures Capital Corp., purchased the land. The land is currently pending the payment of delinquent property taxes that would allow for the Okanogan County Assessor to sub-divide the property, so that the appropriate portion could be deeded to the joint venture. Although Bougainville represented it would pay the delinquent taxes, it has not. To date, the property has not been deeded to the joint venture.

To clarify the respective contributions and roles of the parties, the Company also offered to enter into good faith negotiations to revise and restate the joint venture agreement with Bougainville. The Company diligently attempted to communicate with Bougainville in good faith to accomplish a revised and restated joint venture agreement, and efforts towards satisfying the conditions to complete the subdivision of the land by the Okanogan County Assessor. However, Bougainville failed to cooperate or communicate with the Company in good faith, and failed to pay the delinquent taxes on the real property that would allow for sub-division and the deeding of the real property to the joint venture.

Company Determines to File Suit. On August 10, 2018, the Company advised its independent auditor that Bougainville did not cooperate or communicate with the Company regarding its requests for information concerning the audit of Bougainville’s receipt and expenditures of funds contributed by the Company in the joint venture agreement. Bougainville had a material obligation to do so under the joint venture agreement. The Company believes that some of the funds it paid to Bougainville were misappropriated and that there was self-dealing with respect to those funds. Additionally, the Company believes that Bougainville misrepresented material facts in the joint venture agreement, as amended, including, but not limited to, Bougainville’s representations that: (i) it had an ownership interest in real property that was to be deeded to the joint venture; (ii) it had an agreement with a Tier 3 # I502 cannabis license holder to grow cannabis on the real property; and, (iii) that clear title to the real property associated with the Tier 3 # I502 license would be deeded to the joint venture thirty days after the Company made its final funding contribution. As a result, on September 20, 2018, the Company filed suit against Bougainville Ventures, Inc., BV-MCOA Management, LLC, Andy Jagpal, Richard Cindric, et al. in Okanogan County Washington Superior Court, case number 18-2- 0045324. The Company’s complaint seeks legal and equitable relief for breach of contract, fraud, breach of fiduciary duty, conversion, recession of the joint venture agreement, an accounting, quiet title to real property in the name of the Company, for the appointment of a receiver, the return to treasury of 15 million shares issued to Bougainville, and, for treble da mages pursuant to the Consumer Protection Act in Washington State. The registrant has filed a lis pendens on the real property. The case is currently in litigation. The Company filed an amended complaint and is pending completion of discovery. 

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not Applicable.

 

 

30  
 
 

PART II.

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. MARKET INFORMATION AND HOLDERS

 

Our common stock trades on OTC Markets OTC Pink Market Tier under the ticker symbol “MCOA”. As of December 31, 2021, there were 404 holders of record of our common stock. The following table sets forth, for the periods indicated, the high and low closing sales prices of our common stock for fiscal years ended December 31, 2021 and 2020:

 

2021     High     Low
  Quarter Ended December 31     $ 0.0032     $0.0010
  Quarter Ended September 30     $ 0.0087     $0.0026
  Quarter Ended June 30     $ 0.0103     $0.0048
  Quarter Ended March 31     $ 0.0398     $0.0038
             
  2020       High     Low
  Quarter Ended December 31     $ 0.0245     $0.0044
  Quarter Ended September 30     $ 0.002     $0.0013
  Quarter Ended June 30     $ 0.0199     $0.0043
  Quarter Ended March 31     $ 0.0623     $0.0157

 

DIVIDEND POLICY

 

We have never declared or paid, and do not anticipate declaring or paying, any cash dividends on our common stock. Instead, we currently anticipate that we will retain all of our future earnings, if any, to fund the operation and expansion of our business and to use as working capital and for other general corporate purposes. Any future determination as to the declaration and payment of dividends, if any, will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant.  

  

UNREGISTERED SALES OF EQUITY SECURITIES

 

The following information represents securities sold by the Company as of December 31, 2021 which were not registered under the Securities Act, and were not previously reported in a Quarterly Report on Form 10-Q, or in a Current Report on Form 8-K (17 CFR 249.308). Included are sales of reacquired securities, as well as new issues, securities issued in exchange for property, services, or other securities, and new securities resulting from the modification of outstanding securities.

 

The following sales of unregistered securities were completed by virtue of convertible notes issued by the Company. The issuances were made in reliance on the exemption from registration provided by Section 4.2. Each beneficial note holder was an “accredited investor” and/or “sophisticated investor” pursuant to Section 501(a)(b) of the Securities Act, who provided the Company with representations, warranties and information concerning their respective qualifications as a “sophisticated investor” and/or “accredited investor.” The Company provided and made available to each note holder full information regarding its business and operations. There was no general solicitation in connection with the offer or sale of the restricted securities. The note holders acquired the restricted common stock for their own account, for investment purposes and not with a view to public resale or distribution thereof.

In 2021, the Company issued an aggregate of 142,946,840 shares of its common stock for services rendered with an estimated fair value of $661,293.

 

In 2021, the Company issued an aggregate of 1,236,181,851 shares of its common stock in settlement of convertible notes payable and accrued interest with an estimated fair value of $2,309,876.

 

31  
 
 

On July 24, 2021, the Company issued an aggregate of 22,500,000 shares of its common stock in conversion of related party notes payable with an estimated fair value of $141,750.

 

In 2021, the Company issued an aggregate of 462,844,406 common shares of its common stock in exchange for exercise of warrants on a cashless basis.

 

In 2021, the Company sold 1,052,297,599 shares of its common stock with a value of $2,201,601.

 

In 2021, the Company issued 3,027,031 shares of its common stock with an estimated value of $8,623 to settle liabilities.

 

In 2021, the Company issued 691,935,484 shares of common stock for investments with an estimated value of $1,300,000.

 

On July 5, 2021, the Company issued 265,164,070 shares of common stock issued for the acquisition of VBF Brands Inc. with an estimated value of $1,617,501.

 

In 2021, the Company issued 109,134,122 shares for amendment to the VBF acquisition consideration with an estimated value of $251,008.

 

In 2020, the Company issued an aggregate of 217,396,427 shares of its common stock for services rendered with an estimated fair value of $785,861.

 

In 2020, the Company issued an aggregate of 2,291,141,317 shares of its common stock in settlement of convertible notes payable and accrued interest with an estimated fair value of $3,916,940.

 

In 2020, the Company issued an aggregate of 21,276,596 shares of its common stock in conversion of related party notes payable with an estimated fair value of $50,000.

 

In 2020, the Company issued an aggregate of 51,054,214 common shares of its common stock in exchange for exercise of warrants on a cashless basis.

 

In 2020, the Company issued 205,582,481 shares of its common stock with an estimated value of $762,723 to settle liabilities.

 

In 2020, the Company sold shares 268,679,513 shares of its common stock for proceeds of $478,686.

ITEM 6. SELECTED FINANCIAL DATA

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

 

32  
 
 

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The statements contained in this report that are not statements of historical fact, including without limitation, statements containing the words “believes,” “expects,” “anticipates” and similar words, constitute forward-looking statements that are subject to a number of risks and uncertainties. From time to time we may make other forward-looking statements. Investors are cautioned that such forward-looking statements are subject to an inherent risk that actual results may materially differ as a result of many factors, including the risks discussed from time to time in this report, including the risks described under “Risk Factors” in any filings we have made with the SEC.

  

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an on-going basis, we evaluate these estimates, including those related to useful lives of real estate assets, cost reimbursement income, bad debts, impairment, net lease intangibles, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There can be no assurance that actual results will not differ from those estimates.

 

Background

 

History and Development of the Company

 

We were incorporated in the State of Utah on October 4, 1985, under the name of Mormon Mint, Inc., and our business focused on the manufacture and marketing of commemorative medallions related to the Church of Jesus Christ of Latter-Day Saints. On January 5, 1999, the Company changed its name to Converge Global, Inc., and subsequently focused on the development and implementation of Internet web content and e-commerce applications. In the period from 2009 to 2014, we operated primarily in the mining exploration business, and in 2015, we left the mining business and began an internet-based marketing business focused on online marketing of service items to the hospitality and food service industry, selling retail product directly to consumers from food distributors via credit card and commercial accounts.

 

On September 4, 2015, Donald Steinberg and Charles Larsen acquired control of the Company through the purchase of 400,000,000 shares of restricted common stock and 10,000,000 shares of Preferred Class A stock for $105,000.00, in equal amounts. On September 9, 2015, Donald Steinberg was appointed Chairman of the Board, Chief Executive Officer and Secretary of the Company. Mr. Larsen was appointed to the Board of Directors. The new management changed the Company’s business plans and operations to focus on emerging opportunities in the cannabis and hemp industries. On December 1, 2015, the Company changed its name to Marijuana Company of America, Inc. and its stock trading symbol to MCOA. On December 6, 2019, a change of control occurred, where Donald Steinberg and Charles Larsen transferred their control shares to directors Robert Coale, Edward Manolos and Jesus Quintero. Also on December 6, 2019, Jesus Quintero, who was appointed as Chief Financial Officer in 2018, was appointed as our Chief Executive Officer. Mr. Quintero is currently our Chief Executive Officer and Chief Financial Officer, and a member of the Board of Directors.

 

We are a publicly listed company quoted on OTC Markets OTC Pink Market Tier under the symbol “MCOA”. We are a Smaller Reporting Company based in Los Angeles, California. Our business includes the research and development of (1) varieties of various species of hemp; (2) beneficial uses of hemp and hemp derivatives; (3) indoor and outdoor cultivation methods for hemp; (4) technology used for cultivation and harvesting of different species of hemp, including but not limited to lighting, venting, irrigation, hydroponics, nutrients and soil; (5) different industrial hemp derived cannabinoids (“CBD”) and the possible health benefits thereof; and, (6) new and improved methods of hemp cannabinoid extraction omitting or eliminating the delta-9 tetrahydrocannabinol “THC” molecule.

 

Marijuana Company of America is a Utah corporation quoted on OTC Markets Pink Tier under the symbol “MCOA”. We are based in Los Angeles, California.

 

33  
 
 

 

We are an owner and operator of licensed cannabis cultivation, processing and dispensary facilities and a developer, producer and distributor of innovative branded cannabis and cannabidiol (“CBD”) products in the United States. We are committed to creating a national distributorship and retail brand portfolio of branded cannabis and CBD products, although as of the date of this filing, marijuana (defined as cannabis containing delta-9 tetrahydrocannabinol concentration of more than 0.3 percent on a dry weight basis) currently remains illegal under U.S. federal law.

 

Through our wholly-owned subsidiary cDistro, Inc., a Nevada corporation, our wholly-owned CBD product distribution business, we distribute hemp and CBD products throughout the United States. Through cDistro, we distribute high quality hemp-derived cannabinoid products, as detailed on our cDistro website, www.cdistro.com. cDistro offers CBD brands along with smoke and vape shop related products to wholesalers, c-stores, specialty retailers, and consumers in North America. Through cDistro, we work exclusively with select manufacturers to deliver retail service and products at wholesale prices

 

Through our wholly owned subsidiary HSmart, Inc., a California corporation, we develop and sell CBD products under the brand name hempSMART™. Our business also includes making selected investments and entering into joint ventures with start-up businesses in the legalized cannabis and hemp industries.

 

Readers are directed to review our detailed disclosures in Item 1, Business; Principal Products and their Markets; Joint Ventures and Investments above. A summary of our investment and joint venture activity follows:

 

Joint Ventures

 

Bougainville Ventures, Inc. Our joint venture with Bougainville Ventures, Inc. is currently in litigation (See Legal Proceedings, Item 3). We recorded an annual impairment in 2017 of $792,500, reflecting the Company’s percentage of ownership of the net book value of the investment. During 2018, the Company recorded equity losses of $37,673 and $11,043 for the first and second quarters respectively, and recorded an annual impairment of $285,986 for the year ended December 31, 2018, at which time we determined the investment to be fully impaired due to Bougainville’s breach of contract and resulting litigation.

 

Global Hemp Group Scio Oregon Joint Venture. On May 8, 2018, we entered into a joint venture with Global Hemp Group, Inc., develop a project to commercialize the cultivation of industrial hemp on a 109 acre parcel of real property owned by the Company and Global Hemp Group in Scio, Oregon, and operating under the Oregon corporation Covered Bridges, Ltd. The joint venture agreement commits the Company to a cash contribution of $600,000 payable on the following funding schedule: $200,000 upon execution of the joint venture agreement; $238,780 by July 31, 2018; $126,445 by October 31, 2018; and, $34,775 by January 31, 2019. The Company has complied with its payments. The 2018 crop of hemp grown on the joint venture’s real property consisted of 33 acres of high yielding CBD hemp grown in an orchard style cultivation on the property. The 2018 harvest consisted of approximately 37,000 high yielding CBD hemp plants producing 24 tons of biomass that produced 48,000 pounds of dried biomass. However, there were delays with Global Hemp Group’s management and maintenance of the business and the biomass that caused degradation to the harvested crop affecting marketability. Additional issues and disputes arose between the Company and Global Hemp Group. These disputes led to the parties entering into a settlement agreement on September 28, 2020, whereby Global Hemp Group agreed to pay the Company $200,000 and issue common stock to the Company equal in value to $185,000 as of September 28, 2020, subject to a non-dilutive protection provision. Additionally, Global Hemp Group agreed to pay the Company $10,000 to cover the Company’s legal fees relating to the Agreement. In exchange for the settlement consideration, the Company agreed to relinquish its ownership interest in the joint venture. 

34  
 
 

Natural Plant Extract of California & Subsidiaries Joint Venture; On April 15, 2019, the Company entered into a joint venture agreement with Natural Plant Extracts of California, Inc. and subsidiaries (“NPE”). The purpose of the joint venture was to utilize NPE’s California and City cannabis licenses to jointly operate a business named “Viva Buds” to operate a licensed cannabis distribution service in California. In exchange for acquiring 20% of NPE’s common stock, the Company agree to pay two million dollars and issue NPE one million dollars’ worth of the Company’s restricted common stock. As of February 3, 2020, the Company was in arrears in its payment obligations under the joint venture agreement, and the parties entered into a settlement and release of all claims terminating the joint venture. The parties agreed to reduce the Company’s  equity ownership in NPE from 20% to 5%. The Company also agreed to pay NPE $85,000 and the balance of $56,085.15 paid in a convertible promissory note issued with terms allowing NPE to convert the note into common stock at a 50% discount to the closing price of MCOA’s common stock as of the maturity date. As of the date of this filing, the Company satisfied its payment obligations under the settlement agreement. Our continuing 5% equity ownership in NPE involves related parties, since Edward Manolos, our director, is also a director and beneficial owner of 18.8% of the common stock in NPE.

Joint Ventures in Brazil and Uruguay; On October 1, 2020, we entered into two Joint Venture Agreements with Marco Guerrero, a director of the Company, dated September 30, 2020, to form joint venture operations in Brazil and in Uruguay to produce, manufacture, market and sell the Company’s hempSMART™ products in Latin America, and will also work to develop and sell hempSMART™ products globally. The Joint Venture Agreements contain equal terms for the formation of joint venture entities in Uruguay and Brazil. The Brazilian joint venture will be headquartered in São Paulo, Brazil, and will be named HempSmart Produtos Naturais Ltda. (“HempSmart Brazil”). The Uruguayan joint venture will be headquartered in Montevideo, Uruguay and will be named Hempsmart Uruguay S.A.S. (“HempSmart Uruguay”). Both are in the development stage.

Investments

 

Share Exchange with Cannabis Global, Inc. On September 30, 2020, the Company entered into a securities exchange agreement with Cannabis Global, Inc. (OTC: CBGL), a Nevada corporation. By virtue of the agreement, the Company issued 650,000,000 shares of its unregistered common stock to Cannabis Global in exchange for 7,222,222 shares of Cannabis Global unregistered common stock. The Company and Cannabis Global also entered into a lock up leak out agreement, which prevents either party from sales of the exchanged shares for a period of 12 months. Thereafter the parties may sell not more than the quantity of shares equaling an aggregate maximum sale value of $20,000 per week, or $80,000 per month until all Shares and Exchange Shares are sold. Our transaction with Cannabis Global, Inc. is material and involves related parties, since Edward Manolos, our director and holder of Preferred Class A stock, is also a director of Cannabis Global, Inc.

Share Exchange with Eco Innovation Group, Inc. On February 26, 2021, we entered into a Share Exchange Agreement with Eco Innovation Group, Inc., a Nevada corporation quoted on OTC Markets Pink (“ECOX”) to acquire the number of shares of ECOX’s common stock, equal in value to $650,000 based on the per-share price of $0.06, in exchange for the number of shares of MCOA common stock equal in value to $650,000 based on the closing price for the trading day immediately preceding the effective date (the “Share Exchange Agreement”).  For both parties, the Share Exchange Agreement contains a “true-up” provision requiring the issuance of additional common stock in the event that a decline in the market value of either parties’ common stock should cause the aggregate value of the stock acquired pursuant to the Share Exchange Agreement to fall below $650,000. Complementary to the Share Exchange Agreement, the Company and ECOX entered into a Lock-Up Agreement dated February 26, 2021 (the “Lock-Up Agreement”), providing that the shares of common stock acquired pursuant to the Share Exchange Agreement shall be subject to a lock-up period preventing its sale for a period of 12 months following issuance and limiting the subsequent sale to aggregate maximum sale value of $20,000 per week, or $80,000 per month. On October 1, 2021, we entered into a First Amendment to Lock-Up Agreement between the Company and Eco Innovation Group, Inc., dated and effective October 1, 2021 (the “Amended Lock-Up Agreement”), which amends that certain Lock-Up Agreement entered into between the Company and Eco Innovation Group, Inc. on February 26, 2021 (the “Original Lock-Up Agreement”). The Amended Lock-Up Agreement amends the Original Lock-Up Agreement in one respect, by amending the initial lock-up period from 12 months following its effective date to 6 months following its effective date. All other terms and conditions of the Original Lock-Up Agreement remain unaffected.

 

35  
 
 

Asset Purchase Agreement with VBF Brands, Inc. On October 6, 2021, the Company, through its wholly owned subsidiary Salinas Diversified Ventures, Inc., a California corporation, entered into an Asset Purchase Agreement, Management Services Agreement, Cooperation Agreement and Employment Agreement with VBF Brands, Inc., a California corporation (“VBF”), a wholly owned subsidiary of Sunset Island Group, Inc., a Colorado corporation (“SIGO”). VBF and SIGO agreed to transfer to the Company all of VBF’s outstanding stock to the Company, and appointed our CEO and CFO Jesus Quintero as President of VBF.

 

VBF owns various fixed assets including machinery and equipment, a lease for a 10,000 square foot facility located at 20420 Spence Road, Salinas, California, 93908, leasehold improvements, good-will, inventory, tradenames including “VBF Brands,” trade secrets, intellectual property, and other tangible and intangible properties, including licenses issued by the City of Salinas, County of Monterey, and the State of California to operate a licensed cannabis nursery, cultivation facility, and operations for the manufacturing and distribution of cannabis and cannabis products.

 

VBF and SIGO agreed to sell and transfer to the Company all of VBF’s outstanding stock, and, by virtue of the Management Services Agreement, appoint Mr. Jesus Quintero as President of VBF, vesting management and control of VBF’s licensed cannabis operations in the Company. Concurrently, VBF and Livacich entered into a Cooperation Agreement, whereby VBF and Livacich agreed to cooperate to facilitate the transfer of ownership of VBF, which includes licenses issued by the City of Salinas, County of Monterey, and the State of California, to operate a cannabis nursery, cultivation facility and manufacturing and distribution operations to the Company. The Company also agreed to retain Livacich as Chief Executive Officer for a term of two years and agreed to compensate her with a salary including a signing cash bonus of $250,000, and a $250,000 performance cash bonus payable after six months after the Effective Date. The bonus is conditioned upon Livacich meeting an agreed to “Net Revenue” target of one million dollars ($1,000,000) from VBF’s operations during the six-month period after closing of the Asset Purchase Agreement, and her compliance with the terms and conditions of this Asset Purchase Agreement, the Management Services Agreement and the Cooperation Agreement.

 

As consideration for the transaction, the Company agreed to assume two secured convertible promissory notes issued by SIGO to St. George Investments, LLC, a Utah limited liability company (“St. George”) (the “SIGO Notes”). The first note was issued December 8, 2017, in the original face amount of $170,000.00, and the second was issued February 13, 2018, in the original face amount of $4,245,000.00. SIGO also issued warrants to St. George to purchase common shares in SIGO, and fifty (50) shares of SIGO’s preferred stock. St. George agreed to cancel the warrants and preferred shares upon the Company’s assumption of the SIGO Notes.

 

Under the Asset Purchase Agreement, the closing is conditioned upon certain conditions precedent, specifically (i) VBF and SIGO’s full corporate authorization, consent and execution of this Agreement; (ii) VBF’s sale to MCOA of 100% of the issued and outstanding shares of VBF; (iii) full corporate authorization, consent compliance with and execution of the Management Services Agreement and Cooperation Agreement; (iv) SIGO’s disclosure of the Agreement on Form 8-K with the Securities and Exchange Commission; (v) full cooperation in MCOA’s financial auditing of VBF in accordance with ASC 805, including providing unrestricted access to all VBF corporate and financial records and providing all necessary cooperation with VBF financial personnel; (vi) full cooperation in aiding and assisting Buyer with its change of ownership applications with the relevant licensing authorities; (vii) the warranty of truthful representations and execution of and compliance with the terms and conditions of the Executive Employment Agreement, Management Services Agreement and the Cooperation Agreement.

 

As of the date of this filing, the conditions precedent to the closing of the Asset Purchase Agreement remain in the process of implementation, so that the Asset Purchase Agreement closing has not yet occurred pursuant to its terms. Legal counsel for MCOA is currently in the process of working with VBF, Salinas Diversified Ventures, and the relevant state and local governments to effect the change of control and license transfers necessary to close the Asset Purchase Agreement.

 

36  
 
 

Results of Operations

 

Year ended December 31, 2021 compared to year ended December 31, 2020

 

The following table presents our operating results for the year ended  December 31, 2021 compared to December 31, 2020:

 

MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020
AUDITED
             
    For the Year ended Dec 31,  
    2021     2020  
REVENUES:            
Sales   $ 1,030,249     $ 267,584  
Related party Sales     —         13,069  
Total Revenues     1,030,249       280,653  
                 
Cost of sales     873,371       159,304  
                 
Gross Profit     156,878       121,349  
             
OPERATING EXPENSES:                
Depreciation and amortization     101,334       5,933  
Selling and marketing     456,983       420,511  
Payroll and related     681,786       411,954  
Stock-based compensation     1,207,945       3,014,888  
General and administrative     2,419,963       1,122,954  
  Total operating expenses     4,868,011       4,976,240  
                 
Net loss from operations     (4,711,133 )     (4,854,891 )
                 
OTHER INCOME (EXPENSES):                
Interest expense, net     (4,302,293 )     (2,999,291 )
Impairment gain (Loss) on Joint Ventures     0       (22,658 )
Income (Loss) on equity investment     (735,178 )     106,305  
Gain (loss) on change in fair value of derivative liabilities     3,852       (4,698,072 )
Unrealized Gain (loss) on trading securities     504,137       248,204  
Realized Gain (loss) on trading securities     (543,200 )     (2,603 )
(Loss) Gain on settlement of debt     (407,635 )     77,624  
Total other income (expense)     (5,480,317 )     (7,290,491 )
                 
Net loss before income taxes     (10,191,450 )     (12,145,382 )
                 
Income taxes (benefit)     —         —    
                 
NET INCOME (LOSS)   $ (10,191,450 )   $ (12,145,382 )
                 
Foreign currency Translation Adjustment     (11,725 )        
Comprehensive Income   $ (10,198,883 )   $ (12,145,382 )
                 
Loss per common share, basic and diluted   $ (0.00 )   $ (0.01 )
                 
Weighted average number of common shares outstanding, basic and diluted (after stock-split)     5,248,075,532       962,029,388  

 

  

 

37  
 
 

 

Revenues

 

Total revenues for the year end December 31, 2021 and December 31, 2020, were $1,030,249 and $280,653, respectively, an increase of $749,596. This increase is attributed to $93,633 of our hempSMART product lines and our new line of businesses which were $901,535 for cDistro, a distributor of hemp and CBD products, and equipment lease rental from our new joint venture of $35,081.

 

The following table identifies our new product offerings in 2021, and the revenues produces from sales of our products in 2021 and 2020 respectively:

 

    2021     2020  
Body   $ 1,400     $ 3,901  
Brain Capsules     3,635       29,135  
Drink Mix     167       2,966  
Drops     42,734       152,121  
Face Moisturizers     2,648       13,951  
Pain Capsules     —         8,308  
Pain Cream     37,753       55,938  
Pet Drops     5,296       14,332  
Bottles - Nic     41,470       —    
Bottles - Salt Nic     20,804       —    
CBD Hempettes     3,913       —    
Disposables - Tobacco Free Nicotine (TFN)     261,719       —    
Kratom     338,735       —    
Other C-Distro Products     148,805       —    
Vape     86,089       —    
MCOA Equipment Lease     35,081       —    
                 
TOTAL   $ 1,030,249     $ 280,653  

 

Related Party Sales

Related party sales contributed $0 and $13,069 to our revenue for 2021 and 2020, respectively. Related party sales are comprised of sales of our hempSMART products to our directors, officers, and sales team members. No related party sales were for services. All sales were made at listed retail prices and were for cash consideration.

 

Costs of Sales

Costs of sales primarily consist of inventory cost and overhead, manufacturing, packaging, warehousing, shipping and direct labor costs directly attributable to our hempSMART products. For the year ended December 31, 2021 and December 31, 2020, our total costs of sales were $873,371 and $159,304, respectively. The increase is attributed to $62,434 for our hempSMART business and our new business line that we acquired during 2021, which were $810,937 for cDistro, a distributor of hemp and CBD products.

 

Gross Profit

For the year ended December 31, 2021 and December 31, 2020, gross profit was $156,878 and $121,349, respectively. This increase was attributed to $66,280 from our hempSMART products and the new business that we acquired during 2021, which was $90,598 for cDistro, a distributor of hemp and CBD products. Gross margins were 15.2% and 43.2% for the years ended December 31, 2021 and December 31, 2020, respectively. The Company has incurred net losses from operations of $4,711,133 and $4,854,891 for the years ended December 31, 2021 and 2020, respectively.

 

 

38  
 
 

The following is a tabular breakdown of expenses related to Selling and Marketing, Payroll and Related expenses, Stock-based Compensation and General and Administrative Expenses:

 

Expense   2021     2020  
Stock Based Compensation   $ 1,207,945     $ 3,014,888  
Legal Expense     495,117       171,680  
Admin Compensation     424,537       163,091  
Consulting Fees     408,047       236,343  
Investor Relation     366,590       123,399  
Travel and Related     299,014       74,244  
Marketing / Media     280,749       136,703  
Officer’s Compensation     269,350       223,356  
Marketing Compensation     157,050       154,430  
Independent Contractor     137,885       47,800  
Insurance Expense     111,327       56,762  
Board of Director Fees     95,000       91,010  
Accounting     92,743       111,810  
Rent Expense     66,582       51,526  
Advertising Promotion     60,296       4,012  
Audit Fee     59,500       74,475  
Office Supplies     26,308       6,741  
Intangible amortization     40,000       —    
Bad Debt Expense     34,359       —    
Website Development Cost     32,320       56,260  
SEC Filing Fees     28,057       16,668  
Security     12,560       —    
Bank Service Charges     10,928       2,120  
Web Sales Commission     6,765       30,632  
UK Contract Compensation     4,274       26,704  
Fees / Licensing     3,617       1,252  
All other expenses, net*     137,091       100,334  
Total Payroll & G&A Expenses   $ 4,868,011     $ 4,976,240  

 

*This represents other individually immaterial General and Administrative expenses in the ordinary course of business that were not compensation to any third-party vendors.

 

Stock-based Compensation decreased by $1,806,943 primarily due to less stock-based compensation issued to officers and employees during the year ended December 31, 2021. Stock compensation was $1,207,945 for the year ended December 31, 2021 as compared to $3,014,888 for the year ended December 31, 2020. Stock based compensation during the year ended December 31, 2021 included $251,008 related to additional shares issued to the former owners of cDistro as part of the merger and share exchange agreement amendment entered into on November 24, 2021, and an additional $234,633 related to additional shares owed under that agreement as of December 31, 2021. Administrative compensation increased to $424,537 in 2021 from $163,091 in 2020, the $261,446 increase was due to new hires during 2021 resulting from the expansion of our business. Overall, selling and marketing increased by $36,472, attributed mainly to marketing and media costs that increased by the amount of $36,472 in 2021, from $420,511 in 2020 to a total of $456,983 in 2021, due to an increase in social media advertising costs that resulted in an increase in sales for the year ended December 31, 2021. Legal expenses increased to $495,117 for the year ended December 31, 2021, from $171,680 in 2020, due primarily to increased compliance and regulatory filing activity associated with our public offerings and corporate governance. Investor relation costs increased by $243,191 during 2021 due to increase in investor and shareholder outreach events and hiring of additional investment firms to increase interactions with the investment community. This also resulted in an increase in travel and related expenses by $144,046 for 2021 over 2020. Director and officer insurance increased to $111,327 during the year ended December 31, 2021 from $56,762 for the year ended December 31, 2020 due to an increase in rates from insurance carriers affiliated with the cannabis industry.  

 

Overall, our total operating expenses in 2021 decreased by 2.2% from 2020, from $4,976,240 to $4,868,011, for the year ended 2021, respectively.

 

 

39  
 
 

 

Stock Compensation for Officers and Directors, 2021 and 2020.

 

Officer and Director   2021   2020
Edward Manolos   $ 20,526     $ 15,600  
Marco Guerrero   $ 25,526     $ —    
Themistocles Psomiadis   $ —       $ 19,010  
Jesus Quintero   $ 501,264     $ 2,502,140  
Tad Milander   $ —       $ 49,350  

 

The 2021 stock compensation bonuses were issued by the Board of Directors pursuant to our Equity Incentive Plan and executive contracts with our directors and officers. Pursuant to our Equity Incentive Plan, the Company has discretion to make stock awards to its affiliates for past services, in lieu of bonuses or other cash compensation, for directors’ compensation or for any other valid purpose. At December 31, 2021, we reviewed the performance of our staff and affiliates, and in making the 2021 awards, determined the awards justified because our staff and affiliates accomplished the following:

 

Our Equity Plan issuances to affiliates as of December 31, 2021 increased by $508,644. This was due to the Company’s performance during 2021 and additional shares issued as there were issues with liquidity to pay cash compensation at times. The balance was in stock-based compensation in 2021 as it was for 2020. This was primarily for shares issued for consulting services as follows:

 

The balance of our stock-based compensation in 2021, as compared to 2020 was for consulting services as follows:

 

    2021 Stock-Based     2020 Stock-Based            
Consultant   Compensation     Compensation     Variance     Nature of Consultant Services Provided
Paula Vetter     10,900       19,065       16,467     Consulting Services - Medical Advisory Specialist for hempSMART during 2021 and 2020
Gloria Lynch     —         70,350       (70,350 )   Bonus as part of Equity Incentive Plan during 2020
Lauren Regier     37,766       41,975       (4,209 )   Consulting Services - Web and graphic design during 2021 and 2020
Danny Rodriguez     15,395       —         15,395     Accounting Services 2021
Eddie Bonet     18,474       —         18,474     Accounting Services 2021
Mario Greco MD     25,011       —         25,011     Medical Advisory 2021
Herlin Soto     18,474       —         18,474     Marketing Research 2021
                             
Alan T. Hawkins     100,000       —         100,000     Legal Advisory services 2021
John Grosso     34,800       —         34,800     Investor Relation services 2021
Cory Battan     34,800       —         34,800     Investor Relation services 2021
Ian Harvey     8,726       —         8,726     Consulting and Marketing Services 2021
Tad Mailander     —         43,950       (43,950 )   Consulting Services - Legal services during 2020
Otto Creative Studio     31,140       31,140       —       Consulting Services - IT services during 2021 and 2020
                             

 

 

40  
 
 

The objective outcomes resulting from the consulting services are summarized as follows:

 

  The Company lowered its expense rate by becoming more efficient, reducing head count, and making efficient and effective cashflow decisions.

  The Company paid off most variable priced convertible notes prior to conversion over the last quarter with funds raised from its Form S-1 registration statement.

 

  The Company successfully negotiated a full settlement of its largest senior convertible note holder at a fixed price, preserving shareholder value and minimizing the impact of the dilutive nature of the notes.

 

  The management team has helped pivot from the legacy affiliate marketing (MLM) model for hempSMART to the new direct to consumer e-commerce marketing model. This required significant changes to the culture, business plan and branding of the products.

 

  The Company successfully drew down on its Form S-1 registration equity line with White Lion and was able to get a second Form S-1 primary offering registration statement effective to obtain funds for operations and expansion.

 

  The Company managed to not only survive during the COVID pandemic, but actually grew and thrived due to key management decisions along the way and the personal sacrifice of our CEO Jesus Quintero, who paid for business expenses for several months on his personal business card to help float the Company during periods where funds were depleted.

 

  The executive management team has overseen significant efforts to expand into South America and move key parts of its supply chain to Uruguay to reduce the cost of goods sold and increase gross margins and overall profitability.

 

  The Company has successfully negotiated acquisitions and deals that resulted in the Company’s market capitalization increasing substantially during the year to enhance shareholder value.

 

  The Company successfully removed over three billion shares that were on reservation with the Transfer Agent during 2021 due to successful settlement of convertible debt, resulting in less dilution and more shares available for financing and acquisitions. 

 

We anticipate continuing to reduce our dependence on stock-based compensation in the future. However, given our present cash position, and because of possible increased operational costs including overhead, product manufacturing and development, and related costs, we may, to the extent necessary, utilize stock-based compensation in the future to compensate key product development, operations and sales and marketing personnel. 

Operating Losses

For the year ended December 31, 2021, operating losses were $4,711,133 or 457% of total revenues, as compared to $4,854,891 or 1,730% of total revenues for the year ended December 31, 2020. This increase of $143,758 was due to continued restructuring and expansion of the Company’s operations. We believe the reduced operating losses incurred in 2021, as compared to 2020, reflect the effectiveness of the Company’s management team in 2021. We expect to continue to reduce our losses as we continue to implement our plan for new sales strategies and cost-cutting measures in the near future until profitability is achieved, which is not certain. Our operations are subject to numerous risks associated with establishing any new business, including unforeseen expenses, delays and complications. There can be no assurance that we will achieve or sustain profitable operations. This increase is attributed to the company's expansion into Latin America and operations attributed to our acquisitions in 2021, one of which is not yet integrated financially.

41  
 
 

Other Income (Expense)

Other income (expense) for the years ended December 31, 2021 and December 31, 2020 included other expenses of $5,480,317 and $7,290,491, respectively. The decrease of $1,810,174 was primarily due to an increase of $1,303,002 in interest expense. This was offset by an increase of $4,701,924 in gain on changes in fair value of derivative liabilities from a loss of $4,698,072 for the year ended December 31, 2020 to a gain of $3,852 for year ended December 31, 2021 and a decrease of $841,484 in losses on equity investment from a gain of $106,305 for the year ended December 31, 2020 as compared to a loss of $735,178 for the year ended December 31, 2021. Also, we reflect a decrease in realized loss on trading securities of $540,597 from a loss of $2,603 for the period ended December 31, 2020 compared to a loss of $543,200 for the year ended December 31, 2021.

Income Tax Expense (Benefit)

We did not have any income tax expense or benefit for the years ended December 31, 2021 and December 31, 2020, respectively.

Net Income (Loss)

As a result of the factors discussed above, net losses for the year ended December 31, 2021 and December 31, 2020 were $10,191,450 and $12,145,382, respectively. For December 31, 2021 and December 31, 2020, these net losses represented 989.2% and 4,328% of total revenues for the respective periods.

 

Segment Information

Accounting Standards Codification subtopic Segment Reporting 280-10 ("ASC 280-10") establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The following table represents the Company’s hempSMART business.

 

hempSMART
STATEMENT OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020
             
    For the Years ended  
    Dec 31, 2021     Dec 31, 2020  
             
Revenues   $ 93,575     $ 280,653  
                 
Cost of Goods Sold     61,267       159,304  
                 
Gross Profit     32,308       121,349  
                 
Expense                
Depreciation Expense     10,103       5,933  
Stock-based Compensation     104,685       207,955  
Selling and Marketing     443,569       393,799  
Payroll and Related expenses     252,123       165,491  
General and Admin Expenses     456,322       217,288  
Total Expense     1,266,802       990,466  
                 
Net Loss from Operations   $ (1,234,494 )   $ (869,117 )

 

The following table represents the Company's cDistro business segment for the years ended December 31, 2021 and 2020 since it was acquired:

 

    For the Years ended
    Dec 31, 2021   Dec 31, 2020
         
         
Revenues   $ 901,535     $ —    
                 
Cost of Goods Sold     810,937       —    
                 
Gross Profit     90,598       —    
                 
Expense                
Depreciation and amortization expense     91,358       —    
Stock-based Compensation     —         —    
Selling and Marketing     4,549       —    
Payroll and Related expenses     110,000       —    
General and Admin Expenses     163,355       —    
Total Expense     369,262       —    
                 
Net Loss from Operations   $ (278,664 )   $ —    

 

42  
 
 

Liquidity and Capital Resources

As of December 31, 2021, and December 31, 2020, our operating activities produced cash used in operations of $3,984,108 and $1,723,950,  respectively. Our primary internal sources of liquidity were provided by an increase in proceeds from the issuance of note payables of $3,295,863 for the year ended December 31, 2021 as compared to $1,017,664 for the year ended December 31, 2020, and a decrease in proceeds from the sale of note payables to a related party of $20,000 in 2021 as compared to $75,000 in repayments to a related party for the year ended December 31, 2020. We saw an increase in proceeds from sales of our common stock to $2,201,601 at December 31, 2021, as compared to $478,685 at December 31, 2020. During the period ended December 31, 2021, we relied upon external financing arrangements to fund our operations. During the year ended December 31, 2020, we entered into several separate financing arrangements with St. George Investments, LLC, a Utah limited liability company, in which we borrowed an aggregate of $2,541,470, the principal of which is convertible into shares of our common stock (see Note 4, Convertible Notes Payable). Our ability to rely upon external financing arrangements to fund operations is not certain, and this may limit our ability to secure future funding from external sources without changes in terms requested by counterparties, changes in the valuation of collateral, and associated risk, each of which is reasonably likely to result in our liquidity decreasing in a material way. We intend to utilize cash on hand, loans and other forms of financing such as the sale of additional equity and debt securities and other credit facilities to conduct our ongoing business, and to also conduct strategic business development and implementation of our business plans generally.

Operating Activities

For the year ended December 31, 2021 and 2020, the Company used cash for operating activities of $3,984,108 and $1,723,950, respectively. Operating activities consist of corporate overhead, product development of our hempSMART™ products, and development of our distribution business. Increases are due primarily to increases in executive compensation, professional fees, and product development costs.

Investing Activities

For the years ended December 31, 2021 and December 31, 2020, net cash used in and provided by investing activities was $216,810 and $118,984, respectively. For the year ended December 31, 2021, the Company used $126,305 and $6,016 for the purchase of equipment, while receiving $125,000 in proceeds from the disposition of an investment during the year ended December 31, 2020, compared to the receipt of $190,401 for the sales of investments during the year ended December 31, 2021.

Financing Activities

For the years ended December 31, 2021 and 2020, financing activities were a source of cash of $4,242,164 and $1,467,704, respectively. For the years ended December 31, 2021 and 2020, this was primarily from proceeds of $3,295,863 and $1,017,664 derived from the issuance of notes payable, and repayment to related parties of $20,000 and $75,000 for the year ended December 31, 2021 and 2020, respectively. The Company received income from the sale of common stock of $2,201,601 and $478,685 for the years ended December 31, 2021 and 2020, respectively. For the year ended December 31, 2020, the Company received proceeds of $35,500 from a Payroll Payment Protection loan from the Small Business Administration and also received proceeds of $10,855 from the sale of trading securities.

We currently do not have sufficient cash and liquidity to meet our anticipated working capital for the next twelve months. Historically, we have financed our operations primarily through private sales of our common stock. If our sales goals for our hempSMART™ products and our distribution business, cDistro, do not materialize as planned, and we are not able to achieve profitable operations at some point in the future, we may have insufficient working capital to maintain our operations as we presently intend to conduct them or to fund our expansion, marketing, and product development plans. There can be no assurance that we will be able to obtain such financing on acceptable terms, or at all.

Off Balance Sheet Arrangements

 

As of December 31, 2021 and December 31, 2020, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

43  
 
 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect amounts reported in those statements. We have made our best estimates of certain amounts contained in our consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. However, application of our accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties, and, as a result, actual results could differ materially from these estimates. Management believes that the estimates, assumptions, and judgments involved in the accounting policies described below have the most significant impact on our consolidated financial statements.

 

We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations. We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary.

 

Cash and Cash Equivalents

We consider all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents are held in operating accounts at a major financial institution.

 

Inventory

Inventory is primarily comprised of products and equipment to be sold to end-customers. Inventory is valued at cost, based on the specific identification method, unless and until the market value for the inventory is lower than cost, in which case an allowance is established to reduce the valuation to market value. As of December 31, 2021, and December 31, 2020, market values of all of our inventory were greater than cost, and accordingly, no such valuation allowance was recognized. The value of inventory on December 31, 2021 and December 31, 2020 was $252,199 and $103,483, respectively.

 

Deposits

Deposits is comprised of advance payments made to third parties, primarily for inventory for which we have not yet taken title. When we take title to inventory for which deposits are made, the related amount is classified as inventory, then recognized as a cost of revenues upon sale (see “Costs of Revenues” below).

 

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets is primarily comprised of advance payments made to third parties for independent contractors’ services or other general expenses. Prepaid services and general expenses are amortized over the applicable periods which approximate the life of the contract or service period. The balance of prepaid insurance at December 31, 2021 and December 31, 2020 was $61,705 and $55,783. The balance of prepaid insurance at December 31, 2021 and December 31, 2020 was $61,705 and $55,783.

 

Accounts Receivable

Accounts receivable are recorded at the net value of face amount less any allowance for doubtful accounts. On a periodic basis, we evaluate our accounts receivable and, based on a method of specific identification of any accounts receivable for which we deem the net realizable value to be less than the gross amounts of accounts receivable recorded, we establish an allowance for doubtful accounts for those balances. In determining our need for an allowance for doubtful accounts, we consider historical experience, analysis of past due amounts, client creditworthiness and any other relevant available information. However, our actual experience may vary from our estimates. If the financial condition of our clients were to deteriorate, resulting in their inability or unwillingness to pay our fees, we may need to record additional allowances or write-offs in future periods. This risk is mitigated to the extent that we collect retainers from our clients prior to performing significant services.

 

The allowance for doubtful accounts, if any, is recorded as a reduction in revenue to the extent the provision relates to fee adjustments and other discretionary pricing adjustments. To the extent the provision relates to a client's inability to make required payments on accounts receivables, the provision is recorded in operating expenses. As of December 31, 2021, and 2020, allowance for doubtful accounts was $3,267 and $0, respectively. For December 31, 2021 and December 31, 2020, we recorded bad debt expense of $34,359 and $9,249, respectively. Net accounts receivable for year end December 31, 2021 and December 31, 2020 were $121,588 and $6,542, respectively. Net accounts receivable for year end December 31, 2021 and December 31, 2020 were $121,588 and $6,542, respectively.

 

44  
 
 

Property and Equipment, net

Property and Equipment is stated at net book value, cost less depreciation. Maintenance and repairs are expensed as incurred. Depreciation of owned equipment is provided using the straight-line method over the estimated useful lives of the assets, ranging from two to seven years. Depreciation of capitalized construction in progress costs, a component of property and equipment, net, begins once the underlying asset is placed into service and is recognized over the estimated useful life. Property and equipment is reviewed for impairment as discussed below under “Accounting for the Impairment of Long-Lived Assets.” We did not capitalize any interest as of December 31, 2021 and as of December 31, 2020.

 

Accounting for the Impairment of Long-Lived Assets

We evaluate long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Upon such an occurrence, recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to forecasted undiscounted net cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. For long-lived assets held for sale, assets are written down to fair value, less cost to sell. Fair value is determined based on discounted cash flows, appraised values or management's estimates, depending upon the nature of the assets. We have recorded $0 and $22,658 in impairment charges related to our JV investments during the years ended December 31, 2021 and 2020, respectively.

 

Beneficial Conversion Feature

If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value at issuance, this feature is characterized as a beneficial conversion feature (“BCF”).  We record a BCF as a debt discount pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ACF”) Topic 470-20 Debt with Conversion and Other Options. In those circumstances, the convertible debt is recorded net of the discount related to the BCF, and we amortize the discount to interest expense over the life of the debt using the effective interest method. 

 

Revenue Recognition

For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective ASU 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current U.S. GAAP. Revenue is now recognized in accordance with FASB ASC Topic 606, Revenue Recognition. The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. We adopted FASB ASC Topic 606 for our reporting period as of the year ended December 31, 2017, which made our implementation of FASB ASC Topic 606 effective in the first quarter of 2018. We decided to implement the modified retrospective transition method to implement FASB ASC Topic 606, with no restatement of the comparative periods presented. Using this transition method, we applied the new standards to all new contracts initiated on/after the effective date. We also decided to apply this method to any incomplete contracts we determine are subject to FASB ASC Topic 606 prospectively. For the years ended December 31, 2021 and 2020, there were no incomplete contracts. As is more fully discussed below, we are of the opinion that none of our contracts for services or products contain significant financing components that require revenue adjustment under FASB ASC Topic 606.

 

45  
 
 

 

Identification of Our Contracts with Our Customers.

Contracts included in our application of FASB ASC Topic 606, consist completely of sales contracts between us and our customers that create enforceable rights and obligations. For the years ended December 31, 2020, and 2019, our sales contracts included the following parties: us, our sales associates and our customers. Our sales contracts were offered by us and our sales associates to our customers directly through our web site. Our sales contracts, and those formalized by our sales associates, are represented by an electronic order form, which contains the contractual elements of offer for sale, acceptance and the provision of consideration consisting of the buyer’s payment, which is concurrent with our delivery of hempSMART™ product. Since our hempSMART™ product sales contracts are consummated upon receipt of the customer’s acceptance of our offer; our concurrent receipt of our customers payment; and, our delivery of the agreed to hempSMART™ product, all parties are equally committed to fulfilling their respective obligations under the sales contracts. Further, the sales contracts specifically identify (1) parties; (2) quantity of hempSMART™ product ordered; (3) price; and, (4) subject, and so each respective party’s rights are identifiable and the payment terms are defined. Since the sales contracts are consummated concurrent with offer, acceptance, payment and delivery of the hempSMART™ product ordered, we recognize revenue and cash flows as the principal from the respective sales contract transactions as they complete. Further, because our sales contracts are offered, accepted and consummated concurrently, our ability to collect revenue is immediate. We receive no payments for agreements that do not qualify as a contract. If customers agree to multiple sales contracts when they are entered into at or near the same time, our policy is to combine those contracts if: (1) the sales contracts are negotiated as a single package; (2) the payment amount of one sales contract is dependent upon another sales contract; (3) our performance obligations of delivering multiple hempSMART™ products can be determined to be part of a single transaction. Since the nature of the entry into and consummation of our sales contracts occur concurrently, there are no changes or modifications to the terms of the sales contracts that would modify the enforceable rights and performance obligations of the parties and that would materially alter the timing of our receipt of revenue from our sales contracts.

Identifying the Performance Obligations in Our Sales Contracts.

In analyzing our sales contracts, our policy is to identify the distinct performance obligations in a sales contract arrangement. In determining our performance obligations under our sales contracts, we consider that the terms and conditions of sales are explicitly outlined in our sales contracts and are so distinct and identifiable within the context of each sales contract, and so are not integrated with other goods, or constitute a modification or customization of other goods in our contracts, or are highly dependent or highly integrated with other goods in our sales contracts. Thus, our performance obligations are singularly related to our promise to provide the hempSMART™ products upon receipt of payment. We offer an assurance warranty on our hempSMART™ products that allows a customer to return any hempSMART™ products within thirty days if not satisfied for any reason. Assurance warranties are not identifiable performance obligations, since they are electable at the whim of the customer for any reason. However, we do account for returns of purchase prices if made. 

Determination of the Price in Our Sales Contracts.

The transaction prices in our sales contract is the amount of consideration we expect to be entitled to for transferring promised hempSMART™ products. The consideration amount is fixed and not variable. The transaction price is allocated to the identified performance obligations in the contract. These allocated amounts are recognized as revenue when or as the performance obligations are fulfilled, which is concurrently upon receipt of payment. There are no future options for a contract when considering and determining the transaction price. We exclude amounts third parties will eventually collect, such as sales tax, when determining the transaction price. Since the timing between receiving consideration and transferring goods or services is immediate, our sales contract do not have a significant financing component, i.e., recognizing revenue at the amount that reflects the cash payment that the customer would have made at the time the goods or services were transferred to them (cash selling price), rather than significantly before or after the goods or services are provided.

 

46  
 
 

Allocation of the Transaction Price of Our Sales Contracts.

Our sales contracts are not considered multi-element arrangements which require the fulfillment of multiple performance obligations. Rather, our sales contracts include one performance obligation in each contract. As such, from the outset, we allocate the total consideration to each performance obligation based on the fixed and determinable standalone selling price, which we believe is an accurate representation of what the price is in each transaction.

Recognition of Revenue when the Performance Obligation is Satisfied.

A performance obligation is satisfied when or as control of the good or service is transferred to the customer. The standard defines control as “the ability to direct the use of, and obtain substantially all of the remaining benefits from, the asset.” (ASC 606-10-20). For performance obligations that are fulfilled at a point in time, revenue is recognized at the fulfillment of the performance obligation. As noted above, our single performance obligation sales contracts are singularly related to our promise to provide the hempSMART™ products to the customer upon receipt of payment, which occurs concurrently and when, upon completion, allows us under our revenue recognition policy to realize revenue.

Regarding our offered financial accounting, bookkeeping and/or real property management consulting services, to date no contracts have been entered into, and thus no reportable revenues have resulted for the fiscal years ended 2021 and 2020.

Product Sales

Revenue from product sales, including delivery fees, FOB shipping point, is recognized when (1) an order is placed by the customer; (2) the price is fixed and determinable when the order is placed; (3) the customer is required to and concurrently pays for the product upon order; and, (4) the product is shipped. The evaluation of our recognition of revenue after the adoption of FASB ASC 606 did not include any judgments or changes to judgments that affected our reporting of revenues, since our product sales, both pre and post adoption of FASB ASC 606, were evaluated using the same standards as noted above, reflecting revenue recognition upon order, payment and shipment, which all occurs concurrently when the order is placed and paid for by the customer, and the product is shipped. Further, given the facts that (1) our customers exercise discretion in determining the timing of when they place their product order; and, (2) the price negotiated in our product sales is fixed and determinable at the time the customer places the order, and there is no delay in shipment, we are of the opinion that our product sales do not indicate or involve any significant customer financing that would materially change the amount of revenue recognized under the sales transaction, or would otherwise contain a significant financing component for us or the customer under FASB ASC Topic 606.

Costs of Revenues

Our policy is to recognize costs of revenue in the same manner in conjunction with revenue recognition. Cost of revenues include the costs directly attributable to revenue recognition and includes compensation and fees for services, travel and other expenses for services and costs of products and equipment. Selling, general and administrative expenses are charged to expense as incurred.

 

Advertising and Promotion Costs

Advertising and promotion costs are included as a component of selling and marketing expense and are expensed as incurred. During the years ended December 31, 2021 and December 31, 2020, these costs were $236,563 and $129,504, respectively.

 

Shipping and Handling Costs

For product and equipment sales, shipping and handling costs are included as a component of cost of revenues.

 

Stock-Based Compensation

Restricted shares are awarded to employees and entitle the grantee to receive shares of restricted common stock at the end of the established vesting period. The fair value of the grant is based on the stock price on the date of grant. We recognize related compensation costs on a straight-line basis over the requisite vesting period of the award, which to date has been one year from the grant date. During the years ended December 31, 2021 and December 31, 2020, stock-based compensation expense for restricted shares was $1,207,945 and $3,014,888, respectively. Compensation expense for warrants and options is based on the fair value of the instruments on the grant date, which is determined using the Black-Scholes valuation model and are expensed over the expected term of the awards.

 

Income Taxes

We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns in accordance with applicable accounting guidance for accounting for income taxes, using currently enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized.  For the year ended December 31, 2021 and December 31, 2020, due to cumulative losses, we recorded a valuation allowance against our deferred tax asset that reduced our income tax benefit for the period to zero. As of December 31, 2021, and December 31, 2020, we had no liabilities related to federal or state income taxes and the carrying value of our deferred tax asset was zero.

 

47  
 
 

Loss Contingencies

From time to time the Company is subject to various legal proceedings and claims that arise in the ordinary course of business. On at least a quarterly basis, consistent with ASC 450-20-50-1C, if the Company determines that there is a reasonable possibility that a material loss may have been incurred, or is reasonably estimable, regardless of whether the Company accrued for such a loss (or any portion of that loss), the Company will confer with its legal counsel, consistent with ASC 450. If the material loss is determinable or reasonably estimable, the Company will record it in its accounts and as a liability on the balance sheet. If the Company determines that such an estimate cannot be made, the Company's policy is to disclose a demonstration of its attempt to estimate the loss or range of losses before concluding that an estimate cannot be made, and to disclose it in the notes to the financial statements under Contingent Liabilities.

 

Net Income (Loss) Per Common Share

We report net income (loss) per common share in accordance with FASB ASC 260, “Earnings per Share.” This statement requires dual presentation of basic and diluted earnings with a reconciliation of the numerator and denominator of the earnings per share computations. Basic net income (loss) per share is computed by dividing net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period and excludes the effects of any potentially dilutive securities. Diluted net income (loss) per share gives effect to any dilutive potential common stock outstanding during the period. The computation does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings.

 

Related Party Transactions

We follow FASB ASC subtopic 850-10, “Related Party Transactions”, for the identification of related parties and disclosure of related party transactions.

 

Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

Material related party transactions are required to be disclosed in the consolidated financial statements, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a) the nature of the relationship(s) involved; b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which statements of operation are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c) the dollar amounts of transactions for each of the periods for which statements of operations are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting Company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

   

 

 

48  
 
 

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 

 

Index to Consolidated Financial Statements

 

 

Report of Independent Registered Public Accounting Firm F-1
   
Consolidated Balance Sheets as of December 31, 2021 and 2020 F-3
   
Consolidated Statements of Operations for the years ended December 31, 2021 and 2020 F-4
   
Consolidated Statement of Shareholders’ Deficit for the years ended December 31, 2021 and 2020 F-5
   
Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020 F-6
   
Notes to Consolidated Financial Statements F-7

 

 

 

49  
 
 

 

 

 

 

FL Office

7951 SW 6th Street, Suite 216

Plantation, FL 33324

Tel: 954-424-2345

Fax: 954-424-2230

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB # 454)

 

To the Board of Directors and Stockholders of

Marijuana Company of America, Inc. (Converge Global, Inc.)

 

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Marijuana Company of America, Inc. and its subsidiaries (“the Company”) as of December 31, 2021 and December 31, 2020 and the related statements of operations, stockholders’ deficit, cash flow and the related notes to consolidated financial statements (collectively referred to as the consolidated financial statements) for the year ended December 31, 2021 and December 31, 2020. In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and December 31, 2020 and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

The Company’s Ability to Continue as a Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has an accumulated deficit, recurring losses, and expects continuing future losses. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s evaluation of the events and conditions and management’s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

 

 

F- 1  
 
 

 

FL Office

7951 SW 6th Street, Suite 216

Plantation, FL 33324

Tel: 954-424-2345

Fax: 954-424-2230

 

 

 

Joint Ventures and Investments

As discussed in Note 4 to the consolidated financial statements, the Company accounted for certain joint ventures under the equity method of accounting. In addition, the Company had investments in publicly traded equity securities and entered share exchange agreements with other publicly traded companies. Some of these investments are Level 2 investments and can be hard to value. In addition, as the securities held at fair value, management must assess securities that are in a significant unrealized loss position for other than temporary impairment. For these securities, management must make difficult and subjective judgments about the ability of the issuer to be able to meet its obligations under terms of the security. These judgments can have a significant impact on the Company’s reported earnings if they should prove to be significantly inaccurate.

 

Our principal audit procedures performed to address the joint ventures included the following:

 

· We reviewed joint venture agreements and discussing with management the nature of the rights conveyed to the Company through the joint venture agreements.
· We reviewed management’s assessment of the activities that would most significantly impact the joint venture’s economic performance and evaluated whether the joint venture agreements provided participating or protective rights to the Company.
· We evaluated transactions with the joint ventures for events which would require reconsideration of previous consolidation conclusions.

 

Our principal audit procedures performed to address the investments included the following:

 

· We evaluated management’s significant accounting policies related to the identification of other than temporary impairment.
· Valuation specialists, with specialized skills and knowledge, were involved in the assessment of the fair values for a sample of Level 2 investments.
· We performed testing over a sample of securities to determine if conclusions reached by management regarding other than temporary impairment were appropriate.

 

Convertible Notes

As discussed in Notes 5 and 6 to the consolidated financial statements, the Company had various debt instruments which included conversion features requiring bifurcation and separate accounting. Management evaluated the required accounting, significant estimates, and judgments around the valuation for these embedded derivatives. These embedded derivatives were initially measured at fair value and have subsequently been remeasured to fair value at each reporting period and at settlement.

 

There is no current observable market for these types of features and, as such, the Company determined the fair value of the embedded derivatives using a binomial option pricing model to measure the fair value of the bifurcated derivative. As a result, a high degree of auditor judgment and effort was required in performing audit procedures to evaluate the conclusions reached by management as well as the inputs to the Company’s binomial option pricing model.

 

Our principal audit procedures performed to address this critical audit matter included the following:

 

· We obtained an understanding of the controls and processes surrounding the evaluation, initial measurement and revaluation of the bifurcated derivatives.
· We evaluated management’s assessment and the conclusions reached to ensure these instruments were recorded in accordance with the relevant accounting guidance.
· We evaluated the fair value of the bifurcated derivatives that included testing the valuation models and assumptions utilized by management. We reviewed and tested the fair value model used, significant assumptions, and underlying data used in the model.

 

 

F- 2  
 
 

 

FL Office

7951 SW 6th Street, Suite 216

Plantation, FL 33324

Tel: 954-424-2345

Fax: 954-424-2230

 

 

 

Goodwill Impairment

As discussed in Note 13 to the consolidated financial statements, the Company’s goodwill was $1,633,557 as of December 31, 2021. The Company’s goodwill was recognized in connection with business acquisitions. In accordance with ASC 350, goodwill is reviewed for impairment at least once a year. As of December 31, 2021, the Company concluded there was no impairment for intangible assets as of such date.

 

We identified the evaluation of the impairment analysis for goodwill as a critical audit matter because of the significant estimates and assumptions management used in the analysis. Performing audit procedures to evaluate the reasonableness of these estimates and assumptions required a high degree of auditor judgment and an increased extent of effort. In addition, the audit effort involved the use of professionals with specialized skill and knowledge.

Our principal audit procedures performed to address the goodwill impairment included the following:

  ● Performed a sensitivity analysis of significant assumptions, particularly as it relates to revenue growth rates and operating margins and evaluating the impact on the fair values that would result from changes in the assumptions.

  ● Utilizing personnel with specialized knowledge and skill in analysis to assist in assessing the appropriateness of the methodology applied in estimating the fair values of the Company’s goodwill and evaluating the reasonableness of certain assumptions used in analysis.

 

 

 

 

/s/ L&L CPAS, PA

L&L CPAS, PA

Certified Public Accountants

Plantation, FL

The United States of America

April 15, 2022

 

 

 

F- 3  
 
 

 

 

             
MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AUDITED
             
      Dec 31, 2021       Dec 31, 2020  
                 
ASSETS                
Current assets:                
Cash     104,024     $ 74,503  
Short-term Investments              239,063  
Accounts receivable, net     211,288       8,640  
Inventory     252,199       103,483  
Prepaid Insurance     61,705       55,783  
Other current assets     2,133,640       56,121  
  Total current assets     2,762,856       537,593  
                 
Property and equipment, net     121,588       6,542  
                 
Other assets:                
Long-term Investments     2,327,357       1,552,001  
Right-of-use-assets              7,858  
Intangible assets, net     1,110,000          
Goodwill     1,633,557           
Security deposit     4,541       2,500  
                 
Total assets     7,959,899       2,106,494  
                 
LIABILITIES AND STOCKHOLDERS' DEFICIT                
Current liabilities:                
Accounts payable     932,760       480,877  
Accrued compensation - related party     42,925       79,214  
Accrued liabilities     270,689       401,461  
Notes payable, related parties     20,000       40,000  
Loans payable PPP Stimulus              35,500  
Convertible notes payable, net of debt discount of $1,659,622 and $808,980, respectively     3,769,449       1,426,894  
Contingent Liability - Acquisition     953,837           
Right-of-use liabilities - current portion              7,858  
Subscriptions payable     989,594       670,000  
Derivative liability     749,756       4,426,057  
  Total current liabilities     7,729,010       7,567,861  
                 
                 
Total liabilities     7,729,010       7,567,861  
                 
Stockholders' deficit:                
Preferred stock, $0.001 par value, 50,000,000 shares authorized                
Class A preferred stock, $0.001 par value, 10,000,000 shares designated, 10,000,000 shares issued and outstanding as of December 31, 2021 and December 31, 2020     10,000       10,000  
Class B preferred stock, $0.001 par value, 5,000,000 shares designated, 2,000,000 shares issued and outstanding as of December 30, 2021 and December 31, 2020     2,000       2,000  
Common stock, $0.001 par value; 15,000,000,000 shares authorized; 7,122,806,264 and 3,136,774,861 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively     7,122,806       3,136,775  
Common stock to be issued, 1,000,000 and 11,892,411 shares, respectively     1,000       11,892  
Additional paid in capital     89,607,853       77,687,561  
Accumulated other Comprehensive Income (loss)     (11,725 )         
Accumulated deficit     (96,501,045 )     (86,309,595 )
  Total stockholders' deficit     230,889       (5,461,367 )
                 
Total liabilities and stockholders' deficit     7,959,899     $ 2,106,494  

 

See the accompanying notes to these audited condensed consolidated financial statements

 

F- 4  
 
 

 

             
MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020
AUDITED
             
    For the Year ended Dec 31,  
    2021     2020  
REVENUES:            
Sales   $ 1,030,249     $ 267,584  
Related party Sales     —         13,069  
Total Revenues     1,030,249       280,653  
                 
Cost of sales     873,371       159,304  
                 
Gross Profit     156,878       121,349  
             
OPERATING EXPENSES:                
Depreciation and amortization     101,334       5,933  
Selling and marketing     456,983       420,511  
Payroll and related     681,786       411,954  
Stock-based compensation     1,207,945       3,014,888  
General and administrative     2,419,963       1,122,954  
  Total operating expenses     4,868,011       4,976,240  
                 
Net loss from operations     (4,711,133 )     (4,854,891 )
                 
OTHER INCOME (EXPENSES):                
Interest expense, net     (4,302,293 )     (2,999,291 )
Impairment gain (Loss) on Joint Ventures     0       (22,658 )
Income (Loss) on equity investment     (735,178 )     106,305  
Gain (loss) on change in fair value of derivative liabilities     3,852       (4,698,072 )
Unrealized Gain (loss) on trading securities     504,137       248,204  
Realized Gain (loss) on trading securities     (543,200 )     (2,603 )
(Loss) Gain on settlement of debt     (407,635 )     77,624  
Total other income (expense)     (5,480,317 )     (7,290,491 )
                 
Net loss before income taxes     (10,191,450 )     (12,145,382 )
                 
Income taxes (benefit)                  
                 
NET INCOME (LOSS)   $ (10,191,450 )   $ (12,145,382 )
                 
Foreign currency Translation Adjustment     (11,725 )        
Comprehensive Income   $ (10,198,883 )   $ (12,145,382 )
                 
Loss per common share, basic and diluted   $ (0.00 )   $ (0.01 )
                 
Weighted average number of common shares outstanding, basic and diluted (after stock-split)     5,248,075,532       962,029,388  

 

 

See the accompanying notes to these audited condensed consolidated financial statements

 

F- 5  
 
 

 

 

                                                                               
MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT
FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020
AUDITED
                                                                               
    Class A Preferred Stock     Class B Preferred Stock     Common Stock     Common Stock to be issued     Stock     Paid In     Accumulated     Accumulated Other Comprehensive        
    Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Subscriptions     Capital     Deficit     Loss     Total  
Balance, December 31, 2019     10,000,000     $ 10,000              $          77,958,081     $ 77,958              $        $        $ 63,467,054     $ (74,164,213 )   $        $ (10,609,201 )
Common stock issued to settle amounts previously accrued     —                                 8,333       8       —                         $ 6,692                         6,700  
Issuance of Preferred stock to officer     —                 2,000,000     $ 2,000       —                  —                         $ 2,227,027                         2,227,027  
Common stock issued for services rendered     —                  —                  217,396,427     $ 217,396       —                         $ 568,465                         785,861  
Common stock issued in settlement of convertible notes payable and accrued interest     —                  —                  2,291,141,317     $ 2,291,141       —                         $ 1,625,799                         3,916,940  
Issuance of common stock for settlement of liabilities                                      205,582,481     $ 205,582       10,892,411     $ 10,892              $ 546,248                         762,723  
Conversion of related party notes payable     —                  —                  21,276,596     $ 21,277       —                         $ 28,723                         50,000  
Common stock issued in exchange for exercise of warrants on a cashless basis     —                  —                  51,054,214     $ 51,054       1,000,000     $ 1,000              $ 375,446                         427,500  
Sale of common stock                     —                 268,679,513     $ 268,680       —                         $ 210,006                         478,686  
Common shares issued in settlement of legal case     —                  —                  677,889     $ 3,678       —                         $ 952,573                         956,251  
Reclassification of derivative liabilities to additional paid in capital     —                  —                  —                  —                        $ 7,679,528                         7,679,528  
Net Loss     —                  —                  —                  —       $ 0                         (12,145,382 )            ($ 12,145,382 )
Balance, December 31, 2020     10,000,000     $ 10,000       2,000,000     $ 2,000       3,136,774,851     $ 3,136,774       11,892,411     $ 11,892     $        $ 77,687,561     $ (86,309,595 )   $        $ (5,461,367 )
                                                                                                         
                                                                                                         
      Class A Preferred Stock       Class B Preferred Stock       Common Stock       Common Stock to be issued       Stock       Paid In       Accumulated       Accumulated Other Comprehensive          
      Shares       Amount       Shares       Amount       Shares       Amount       Shares       Amount       Subscriptions       Capital       Deficit       Loss       Total  
Balance, December 31, 2020     10,000,000     $ 10,000       2,000,000     $ 2,000       3,136,774,851     $ 3,136,774       11,892,411     $ 11,892     $        $ 77,687,561     $ (86,309,595 )   $        $ (5,461,367 )
Common stock issued to settle amounts previously accrued     —                  —                  —                  —                           0                             
Issuance of Preferred stock to officer     —                  —       $          —                  —                           0     $                       
Common stock issued for services rendered     —                                  142,946,860       142,947       —                          518,345                        661,292  
Common stock issued in settlement of convertible notes payable and accrued interest     —                  —                  1,236,181,851       1,236,181       —                           1,073,693                         2,309,874  
Issuance of common stock for settlement of liabilities     —                  —                  3,027,031       3,027       (10,892,411 )     (10,892 )              16,488                        8,623  
Conversion of related party notes payable and accounts payable     —                  —                  22,500,000       22,500       —                           119,250                         141,750  
Common stock issued in exchange for exercise of warrants on a cashless basis     —                  —                  462,844,406       462,844       —                           (462,844 )                           
Sale of common stock     —                  —                  1,052,297,599       1,052,298       —                          1,149,303                         2,201,601  
Issuance of common stock for investments     —                  —                  691,935,484       691,935       691,935                         608,065                        1,300,000  
Reclassification of derivative liabilities to additional paid in capital     —                  —                  —                  —                           6,483,762                         6,483,762  
Debt discount from warrants issued with convertible notes payable     —                  —                  —                  —                           716,953                         716,953  
Common stock issued for acquisition of business     —                  —                  265,164,070       265,164       —                           1,352,337                         1,617,501  
Common stock issued for amendment to acquisition consideration     —                  —                  109,134,122       109,134       —                           141,874                         251,008  
Modification of Notes Payable     —                  —                  —                  —                           203,066                         203,066  
Net Loss     —                  —                  —                  —                                    (10,191,450 )     (11,725 )     (10,203,174 )
Balance, December 31, 2021     10,000,000     $ 10,000       2,000,000     $ 2,000       7,122,806,264     $ 7,122,805       1,691,935     $ 1,000     $        $ 89,607,853     $ (96,501,045 )   $ (11,725 )   $ 230,889  

 

 

 

See the accompanying notes to these audited condensed consolidated financial statements

 

 

F- 6  
 
 

 

MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2021 AND 2020

AUDITED

         
      2021       2020  
CASH FLOWS FROM OPERATING ACTIVITIES:                
Net Income (Loss)   $ (10,191,450 )   $ (12,145,382 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Amortization of debt discount     1,993,373       1,658,395  
Depreciation and amortization     101,334       5,933  
Bad debt expense     34,359           
Impairment loss on equity investment                 
Loss on equity investment     735,178           
Loss (Gain) on change in fair value of derivative liability     (3,852 )     4,698,072  
Interest expense recognized for the excess of fair value of derivative liability over net book value of notes payable at issuance     1,900,836       792,321  
Loss on share inducement and settlement of warrant liability              163,885  
Stock-based compensation     1,146,933       3,014,888  
Unrealized (Gain) Loss on trading securities     39,063       (248,204 )
Realized Loss on trading securities             2,603  
Gain on Settlement of joint venture              (77,624 )
Loss on settlement of liabilities     407,635           
Changes in operating assets and liabilities:                
Accounts receivable     (210,132 )     9,677  
Inventories     (140,900 )     45,692  
Prepaid expenses and other current assets     (314,056 )     (100,870 )
Notes receivable             75,000  
Accounts payable     382,355       (45,706 )
Accrued expenses and other current liabilities     135,216       427,488  
Right-of-use assets     7,858       14,243  
Right-of-use liabilities     (7,858 )     (14,361 )
Net cash provided by (used in) operating activities     (3,984,108 )     (1,723,950 )
                 
Cash flows from investing activities:                
Purchases of property and equipment     (126,305 )     (6,016 )
                 
Payment to establish joint venture     (125,356 )         
Proceeds from sale of investments     190,401       125,000  
Investment in joint venture                 
Acquisition of business     (155,550 )         
Net cash provided by (used in) investing activities     (216,810 )     118,984  
                 
Cash flows from financing activities:                
Proceeds from issuance of notes payable     3,295,863       1,017,664  
Proceeds from PPP loan payable              35,500  
Proceeds from sales of trading securities              10,855  
Repayments of notes payable     (1,235,300 )         
Repayments to related parties     (20,000 )     (75,000 )
Proceeds from sale of common stock     2,201,601       478,685  
Net cash provided by (used in) financing activities     4,242,164       1,467,704  
                 
Foreign exchange impact on cash     (11,725 )         
                 
Net increase (decrease) in cash     29,521       (137,262 )
                 
Cash at beginning of period     74,503       211,765  
                 
Cash at end of period   $ 104,024     $ 74,503  
      —            
Supplemental disclosure of cash flow information:                
Cash paid for interest                  
Cash paid for taxes                  
                 
Non cash financing activities:                
Common stock issued in settlement of convertible notes payable   $ 2,309,874     $ 2,635,647  
Common stock issued in settlement of related party notes payable and accrued compensation           $ 50,613  
Reclassification of derivative liabilities to additional paid-in capital   $ 6,483,762     $ 3,886,971  
Gains on settlement of JV investment   $        $ 386,930  
Common stock issued for investment   $ 1,300,000     $     
Common stock issued to settle liabilities   $ 8,623     $     
Common stock issued for acquisition of business   $ 1,617,501     $     
Common shares issued in settlement of legal case   $        $ 1,283,632  

 

See the accompanying notes to these audited condensed consolidated financial statements

 

 

F- 7  
 
 

 

MARIJUANA COMPANY OF AMERICA, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020

 

NOTE 1 — SIGNIFICANT ACCOUNTING POLICIES

A summary of the significant accounting policies applied in the presentation of the accompanying financial statements follows:

Basis and business presentation

Marijuana Company of America, Inc. (The “Company”) was incorporated under the laws of the State of Utah in October 1985 under the name Mormon Mint, Inc. The corporation was originally a startup company organized to manufacture and market commemorative medallions related to the Church of Jesus Christ of Latter Day Saints. On January 5, 1999, Bekam Investments, Ltd. acquired one hundred percent of the common shares of the Company and spun the Company off changing its name Converge Global, Inc. From August 13, 1999 until November 20, 2002, the Company focused on the development and implementation of Internet web content and e-commerce applications. In October 2009, in a 30 for 1 exchange, the Company merged with Sparrowtech, Inc. for the purpose of exploration and development of commercially viable mining properties. From 2009 to 2014, we operated primarily in the mining exploration business.

In 2015, the Company changed its business model to a marketing and distribution company for medical marijuana. In conjunction with the change, the Company changed its name to Marijuana Company of America, Inc. At the time of the transition in 2015, there were no remaining assets, liabilities or operating activities of the mining business.

On September 21, 2015, the Company formed H Smart, Inc, a Delaware corporation as a wholly owned subsidiary for the purpose of operating the hempSMART brand. H Smart, Inc. is also registered with the California Secretary of State as a foreign corporation.

On February 1, 2016, the Company formed MCOA CA, Inc., a California corporation as a wholly owned subsidiary to facilitate mergers, acquisitions and the offering of investments or loans to the Company.

On May 3, 2017, the Company formed Hempsmart Limited, a United Kingdom corporation as a wholly owned subsidiary for the purpose of future expansion into the European market.

On May 23, 2018, the Company formed H Smart, LLC in Washington State. On January 21, 2019, the Company converted this entity into a Washington State corporation named H Smart, Inc.

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: H Smart, Inc., H Smart, LLC, Hempsmart Limited and MCOA CA, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

Revenue Recognition

For annual reporting periods after December 15, 2017, the Financial Accounting Standards Board (“FASB”) made effective ASU 2014-09 “Revenue from Contracts with Customers,” to supersede previous revenue recognition guidance under current U.S. GAAP. Revenue is now recognized in accordance with FASB ASC Topic 606, Revenue Recognition. The objective of the guidance is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The core principal is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. Two options were made available for implementation of the standard: the full retrospective approach or modified retrospective approach. The guidance became effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted. We adopted FASB ASC Topic 606 for our reporting period as of the year ended December 31, 2017, which made our implementation of FASB ASC Topic 606 effective in the first quarter of 2018. We decided to implement the modified retrospective transition method to implement FASB ASC Topic 606, with no restatement of the comparative periods presented. Using this transition method, we applied the new standards to all new contracts initiated on/after the effective date. We also decided to apply this method to any incomplete contracts we determine are subject to FASB ASC Topic 606 prospectively. For the year ended December 31, 2021, there were no incomplete contracts. As is more fully discussed below, we are of the opinion that none of our contracts for services or products contain significant financing components that require revenue adjustment under FASB ASC Topic 606. 

 

F- 8  
 
 

 

 

Identification of Our Contracts with Our Customers.

Contracts included in our application of FASB ASC Topic 606, consist completely of sales contracts between us and our customers that create enforceable rights and obligations. For the year ended December 31, 2021, our sales contracts included the following parties: us, our sales associates and our customers. Our sales contracts were offered by us and our sales associates to our customers directly through our web site. Our sales contracts, and those formalized by our sales associates, are represented by an electronic order form, which contains the contractual elements of offer for sale, acceptance and the provision of consideration consisting of the buyer’s payment, which is concurrent with our delivery of hempSMART™ product. Since our hempSMART™ product sales contracts are consummated upon receipt of the customer’s acceptance of our offer; our concurrent receipt of our customers payment; and, our delivery of the agreed to hempSMART™ product, all parties are equally committed to fulfilling their respective obligations under the sales contracts. Further, the sales contracts specifically identify (1) parties; (2) quantity of hempSMART™ product ordered; (3) price; and, (4) subject, and so each respective party’s rights are identifiable and the payment terms are defined. Since the sales contracts are consummated concurrent with offer, acceptance, payment and delivery of the hempSMART™ product ordered, we recognize revenue and cash flows as the principal from the respective sales contract transactions as they complete. Further, because our sales contracts are offered, accepted and consummated concurrently, our ability to collect revenue is immediate. We receive no payments for agreements that do not qualify as a contract. If customers agree to multiple sales contracts when they are entered into at or near the same time, our policy is to combine those contracts if: (1) the sales contracts are negotiated as a single package; (2) the payment amount of one sales contract is dependent upon another sales contract; (3) our performance obligations of delivering multiple hempSMART™ products can be determined to be part of a single transaction. Since the nature of the entry into and consummation of our sales contracts occur concurrently, there are no changes or modifications to the terms of the sales contracts that would modify the enforceable rights and performance obligations of the parties and that would materially alter the timing of our receipt of revenue from our sales contracts.

Identifying the Performance Obligations in Our Sales Contracts.

In analyzing our sales contracts, our policy is to identify the distinct performance obligations in a sales contract arrangement. In determining our performance obligations under our sales contracts, we consider that the terms and conditions of sales are explicitly outlined in our sales contracts and are so distinct and identifiable within the context of each sales contract, and so are not integrated with other goods, or constitute a modification or customization of other goods in our contracts, or are highly dependent or highly integrated with other goods in our sales contracts. Thus, our performance obligations are singularly related to our promise to provide the hempSMART™ products upon receipt of payment. We offer an assurance warranty on our hempSMART™ products that allows a customer to return any hempSMART™ products within thirty days if not satisfied for any reason. Assurance warranties are not identifiable performance obligations, since they are electable at the whim of the customer for any reason. However, we do account for returns of purchase prices if made.

Determination of the Price in Our Sales Contracts.

The transaction prices in our sales contract is the amount of consideration we expect to be entitled to for transferring promised hempSMART™ products. The consideration amount is fixed and not variable. The transaction price is allocated to the identified performance obligations in the contract. These allocated amounts are recognized as revenue when or as the performance obligations are fulfilled, which is concurrently upon receipt of payment. There are no future options for a contract when considering and determining the transaction price. We exclude amounts third parties will eventually collect, such as sales tax, when determining the transaction price. Since the timing between receiving consideration and transferring goods or services is immediate, our sales contract do not have a significant financing component, i.e., recognizing revenue at the amount that reflects the cash payment that the customer would have made at the time the goods or services were transferred to them (cash selling price), rather than significantly before or after the goods or services are provided. 

F- 9  
 
 

 

Allocation of the Transaction Price of Our Sales Contracts.

Our sales contracts are not considered multi-element arrangements which require the fulfillment of multiple performance obligations. Rather, our sales contracts include one performance obligation in each contract. As such, from the outset, we allocate the total consideration to each performance obligation based on the fixed and determinable standalone selling price, which we believe is an accurate representation of what the price is in each transaction.

Recognition of Revenue when the Performance Obligation is Satisfied.

A performance obligation is satisfied when or as control of the good or service is transferred to the customer. The standard defines control as “the ability to direct the use of, and obtain substantially all of the remaining benefits from, the asset.” (ASC 606-10-20). For performance obligations that are fulfilled at a point in time, revenue is recognized at the fulfillment of the performance obligation. As noted above, our single performance obligation sales contracts are singularly related to our promise to provide the hempSMART™ products to the customer upon receipt of payment, which occurs concurrently and when, upon completion, allows us under our revenue recognition policy to realize revenue.

Product Sales

Revenue from product sales, including delivery fees, FOB shipping point, is recognized when (1) an order is placed by the customer; (2) the price is fixed and determinable when the order is placed; (3) the customer is required to and concurrently pays for the product upon order; and, (4) the product is shipped. The evaluation of our recognition of revenue after the adoption of FASB ASC 606 did not include any judgments or changes to judgments that affected our reporting of revenues, since our product sales, both pre and post adoption of FASB ASC 606, were evaluated using the same standards as noted above, reflecting revenue recognition upon order, payment and shipment, which all occurs concurrently when the order is placed and paid for by the customer, and the product is shipped. Further, given the facts that (1) our customers exercise discretion in determining the timing of when they place their product order; and, (2) the price negotiated in our product sales is fixed and determinable at the time the customer places the order, and there is no delay in shipment, we are of the opinion that our product sales do not indicate or involve any significant customer financing that would materially change the amount of revenue recognized under the sales transaction, or would otherwise contain a significant financing component for us or the customer under FASB ASC Topic 606.

The Company determined that upon adoption of ASC 606 there were no quantitative adjustments converting from ASC 605 to ASC 606 respecting the timing of our revenue recognition because product sales revenue is recognized upon customer order, payment and shipment, which occurs concurrently.

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

 

Cash

 

The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.

 

Concentrations of credit risk

 

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

 

Accounts Receivable

 

Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus, trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Net accounts receivable for year end December 31, 2021 and December 31, 2020 were $121,588 and $6,542, respectively.

 

Allowance for Doubtful Accounts

 

Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2021, and 2020, allowance for doubtful accounts was $3,267 and $0, respectively.

 

F- 10  
 
 

 

Inventories

 

Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs. The value of inventory on December 31, 2021 and December 31, 2020 was $252,199 and $103,483, respectively .